Modulating Robo: ligand interactions

Abstract

Disclosed are methods and compositions for identifing agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.

Description

INTRODUCTION

1. Field of the Invention

The field of this invention is methods for modulating nerve cell function.

2. Background

In the developing CNS, most growth cones confront the midline at one or multiple times during their journey and make the decision of whether to cross or not to cross. This decision is not a static one but rather changes according to the growth cone's history. For example, in the Drosophila ventral nerve cord, about 10% of the intemeurons project their axons only on their own side, in some cases extending near the midline without crossing it The other 90% of the interneurons first project their axons across the midline and then turn to project longitudinally on the other side, often extending near the midline. These growth cones, having crossed the midline once, never cross it again, in spite of their close proximity to the midline and the many commissural axons crossing it. This decision to cross or not to cross is not unique to Drosophila but is common to a variety of midline structures in all bilaterally symmetric nervous systems.

What midline signals and growth cone receptors control whether growth cones do or do not cross the midline? After crossing once, what mechanism prevents these growth cones from crossing again? A related issue concerns the nature of the midline as an intermediate target. If so many growth cones find the midline such an attractive structure, why do they cross over it rather than linger? Why do they leave the midline?

One approach to find the genes encoding the components of such a system is to screen for mutations in which either too many or too few axons cross the midline. Such a large-scale mutant screen was previously conducted in Drosophila, and led to the identification of two key genes: commissureless (comm) and roundabout (robo) (Seeger et al., 1993; reviewed by Tear et al., 1993). In comm mutant embryos, commissural growth cones initially orient toward the midline but then fail to cross it and instead recoil and extend on their own side. robo mutant embryos, on the other hand, display the opposite phenotype in that too many axons cross the midline; many growth cones that normally extend only on their own side instead now project across the midline and axons that normally cross the midline only once instead appear to cross and recross multiple times (Seeger et al, 1993; present disclosure). Double mutants of comm and robo display a robo-like phenotype.

How do comm and robo function to control midline crossing? Neither the initial paper on these genes (Seeger et al., 1993) nor the cloning of comm (Tear et al., 1996) resolved this question. comm encodes a novel surface protein expressed on midline cells. In fact, the comm paper (Tear et al., 1996) ended with the hope that future work would ". . . help shed some light on the enigmatic function of Comm."

U.S. Ser. No. 08/971,172 (Robo, A Novel Family of Polypeptides and Nucleic Acids, by inventors: Corey S. Goodman, Thomas Kidd, Kevin J. Mitchell and Guy Tear) discloses the cloning and characterization of robo in various species including Drosophila; Robo polypeptides and polypeptide-encoding nucleic acids are also disclosed and their genbank accession numbers referenced in Kidd et al. (1998) Cell 92, 205-215. robo encodes a new class of guidance receptor with 5 immunoglobulin (Ig) domains, 3 fibronectin type III domains, a transmembrane domain, and a long cytoplasmic domain. Robo defines a new subfamily of Ig superfamily proteins that is highly conserved from fruit flies to mammals. The Robo ectodomains, and in particular the first two Ig domains, are highly conserved from fruit fly to human, while the cytoplasmic domains are more divergent. Nevertheless, the cytoplasmic domains contain three highly conserved short proline-rich motifs which may represent binding sites for SH3 or other binding domains in linker or signaling molecules.

For those axons that never cross the midline, Robo is expressed on their growth cones from the outset; for the majority of axons that do cross the midline, Robo is expressed at high levels on their growth cones only after they cross the midline. Transgenic rescue experiments in Drosophila reveal that Robo can function in a cell autonomous fashion, consistent with it functioning as a receptor. Thus, in Drosophila, Robo appears to function as the gatekeeper controlling midline crossing; growth cones expressing high levels of Robo are prevented from crossing the midline. Robo proteins in mammals function in a similar manner in controlling axon guidance.

U.S. Ser. No. 60/065,54 (Methods for Modulating Nerve Cell Function, by inventors: Corey S. Goodman, Thomas Kidd, Guy Tear, Claire Russell and Kevin Mitchell) discloses ectopic and overexpression studies revealing that Comm down-regulates Robo expression, demonstrating that Comm functions to suppress the Robo-mediated midline repulsion. These results show that the levels of Comm at the midline and Robo on growth cones are tightly intertwined and dynamically regulated to assure that only certain growth cones cross the midline, that those growth cones that cross do not linger at the midline, and that once they cross they never do so again.

Relevant Literature Seeger, M., Tear, G., Ferres-Marco, D. and Goodmnan C. S. (1993) Neuron 10, 409-426; Tear G., et al. (1996) Neuron 16, 501-514; Rothberg et al. (1990) Genes Dev 4, 2169-2187; Kidd et al. (1998) Cell 92, 205-215.

SUMMARY OF THE INVENTION

The invention provides methods and compositions relating to vertebrate Slit1 and Slit2, collectively vertebrate Slit) polypeptides, related nucleic acids, polypeptide domains thereof having vertebrate Slit-specific structure and activity, and modulators of vertebrate Slit function. Vertebrate Slit polypeptides can regulate cell, especially nerve cell, function and morphology. The polypeptides may be produced recombinantly from transformed host cells from the subject vertebrate Slit polypeptide encoding nucleic acids or purified from mammalian cells. The invention provides isolated vertebrate Slit hybridization probes and primers capable of specifically hybridizing with natural vertebrate Slit genes, vertebrate Slit-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for vertebrate Slit transcripts), therapy (e.g. to modulate nerve cell growth) and in the biopharmaceutical industry (e.g. as immunogens, reagents for isolating vertebrate Slit genes and polypeptides, reagents for screening chemical libraries for lead pharmacological agents, etc.).

The invention also provides methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.

DETAILED DESCRIPTION OF THE INVENTION

The subject methods include screens for agents which modulate Robo:ligand interactions and methods for modulating Robo:ligand interactions. Robo activation is found to regulate a wide variety of cell functions, including cell-cell interactions, cell mobility, morphology, etc. Slit polypeptides are disclosed as specific activators and inactivators of Robo polypeptides. Accordingly, the invention provides methods for modulating targeted cell function comprising the step of modulating Robo activation by contacting the cell with a modulator of a Robo:Slit interaction.

The targeted Robo polypeptide is generally naturally expressed on the targeted cells. The nucleotide sequences of exemplary natural cDNAs encoding drosophila 1, drosophila 2, C. elegans, human 1, human 2 and mouse 1 Robo polypeptides and their translates are described in Kidd et al. (1998) Cell 92, 205-215 and U.S. Ser. No. 08/971,172. The targeted Robo polypeptides comprise at least a functional Robo domain, which domain has Robo-specific amino acid sequence and binding specificity or function. Preferred Robo domains comprise at least 8, preferably at least 16, more preferably at least 32, most preferably at least 64 consecutive residues of a natural full length Robo. In a particular embodiment, the domains comprise one or more structural/functional Robo immunoglobulin, fibronectin or cytoplasmic motif domains described herein. The subject domains provide Robo-specific antigens and/or immunogens, especially when coupled to carrier proteins. For example, peptides corresponding to Robo- and human Robo-specific domains are covalently coupled to keyhole limpet antigen (KLH) and the conjugate is emulsified in Freunds complete adjuvant. Laboratory rabbits are immunized according to conventional protocol and bled. The presence of Robo-specific antibodies is assayed by solid phase immunosorbant assays using immobilized Robo polypeptides. Generic Robo-specific peptides are readily apparent as conserved regions in aligned Robo polypeptide sequences. In addition, species-specific antigenic and/or immunogenic peptides are readily apparent as diverged extracellular or cytosolic regions in alignments Human Robo-specific antibodies are characterized as uncross-reactive with non-human Robo polypeptides.

The subject domains provide Robo domain specific activity or function, such as Robo-specific cell, especially neuron modulating or modulating inhibitory activity, Robo-ligand-binding or binding inhibitory activity. Robo-specific activity or function may be determined by convenient in vitro, cell-based, or in vivo assays: e.g. in vitro binding assays, cell culture assays, in animals (e.g. gene therapy, transgenics, etc.), etc. The binding target may be a natural intracellular binding target, a Robo regulating protein or other regulator that directly modulates Robo activity or its localization; or non-natural binding target such as a specific immune protein such as an antibody, or a Robo specific agent such as those identified in screening assays such as described below. Robo-binding specificity may be assayed by binding equilibrium constants (usually at least about 10.sup.7 M.sup.-1, preferably at least about 10.sup.8 M.sup.-1, more preferably at least about 10.sup.9 M.sup.-1), by the ability of the subject polypeptide to function as negative mutants in Robo-expressing cells, to elicit Robo specific antibody in a heterologous host (e.g a rodent or rabbit), etc.

Similarly, the Slit polypeptide is conveniently selected from Slit polypeptides which specifically activate or inhibit the activation of the Robo polypeptide. Exemplary suitable Slit polypeptides (a) comprises a vertebrate Slit sequence disclosed herein, especially human Slit-1 (SEQ ID NO:02), or a deletion mutant thereof which specifically modulates Robo expression or a sequence about 60-70%, preferably about 70-80%, more preferably about 80-90%, more preferably about 90-95%, most preferably about 95-99% similar to a vertebrate Slit sequence disclosed herein as determined by Best Fit analysis using default settings and is other than a natural drosophila Slit sequence, preferably other than a natural invertebrate Slit sequence, and/or (b) is encoded by a nucleic acid comprising a natural Slit encoding sequence (such as a natural human Slit-1 encoding sequence, SEQ ID NO:01) or a fragment thereof at least 36, preferably at least 72, more preferably at least 144, most preferably at least 288 nucleotides in length which specifically hybridizes thereto. Suitable deletion mutants are readily screened in Robo binding or activation assays as described herein. Preferred Slit domains/deletion mutants/fragments comprise at least 8, preferably at least 16, more preferably at least 32, most preferably at least 64 consecutive residues of a disclosed vertebrate Slit sequences and provide a Slit specific activity, such as Slit-specific antigenicity and/or immunogenicity, especially when coupled to carrier proteins as described above for Robo above. Suitable natural Slit encoding sequence fragements are of length sufficient to encode such Slit domains. In a particular embodiment, the Slit fragments comprise species specific fragments; such fragments are readily discerned from alignments of the disclosed sequences, see, e.g. shown as unboxed sequences in Tables 1 and 2. Exemplary such human Slit-1 immunogenic and/or antigenic peptides are shown in Table 3.

TABLE 1__________________________________________________________________________Alignment of human Slit-1 (SEQ ID NO:02), human Slit-2 (SEQ ID NOS:03-06), Drosophila Slit-1 (SEQ ID NO:07), C. elegans Slit-1 (SEQ ID NOS:08-09), mouseSlit-2 (SEQ ID NOS:10- 11) and mouse Slit-1 (SEQ ID NOS:12-14).__________________________________________________________________________ #STR1## - #STR2## - #STR3## - #STR4## - #STR5## - #STR6## - #STR7## - #STR8## - #STR9## - #STR10## - #STR11## - #STR12## - #STR13## - #STR14## - #STR15## - #STR16## - #STR17## - #STR18## - #STR19## - #STR20## - #STR21## - #STR22## - #STR23## - #STR24## - #STR25## - #STR26## - #STR27## - #STR28## - #STR29## - #STR30## - #STR31## - #STR32## - #STR33## - #STR34## - #STR35## - #STR36## - #STR37## - #STR38## - #STR39## - #STR40## - ##STR41##__________________________________________________________________________ TABLE 2__________________________________________________________________________Alignment of human Slit-1 (SEQ ID NO:02) and Drosophila Slit-1 (SEQ IDNO:07)__________________________________________________________________________ #STR42## #STR43## - #STR44## - #STR45## - #STR46## - #STR47## - #STR48## - #STR49## - #STR50## - #STR51## - #STR52## - #STR53## - #STR54## - #STR55## - #STR56## - #STR57## - #STR58## - #STR59## - #STR60## - #STR61## - #STR62## - #STR63## - #STR64## - #STR65## - #STR66## - #STR67## - #STR68## - #STR69## - #STR70## - #STR71## - #STR72## - #STR73## - #STR74## - #STR75## - #STR76## - #STR77## - #STR78## - #STR79## - #STR80## - ##STR81##__________________________________________________________________________ TABLE 3__________________________________________________________________________Immunogenic human Slit-1 polypeptides eliciting Slit-1 specific rabbitpolyclonal antibody: Slit polypeptide-KLH conjugates immunized per protocoldescribed above.Slit Polypeptide Immunogenicity Slit Polypeptide Immunogenicity__________________________________________________________________________SEQ ID NO: 02, res. 1-10 +++ SEQ ID NO: 02, res. 561-576 +++ SEQ ID NO: 02, res. 29-41 +++ SEQ ID NO: 02, res. 683-697 +++ SEQ ID NO: 02, res. 75-87 +++ SEQ ID NO: 02, res. 768-777 +++ SEQ ID NO: 02, res. 92-109 +++ SEQ ID NO: 02, res. 798-813 +++ SEQ ID NO: 02, res. 132-141 +++ SEQ ID NO: 02, res. 882-894 +++ SEQ ID NO: 02, res. 192-205 +++ SEQ ID NO: 02, res. 934-946 +++ SEQ ID NO: 02, res. 258-269 +++ SEQ ID NO: 02, res. 1054-1067 +++ SEQ ID NO: 02, res. 295-311 +++ SEQ ID NO: 02, res. 1181-1192 +++ SEQ ID NO: 02, res. 316-330 +++ SEQ ID NO: 02, res. 1273-1299 +++ SEQ ID NO: 02, res. 373-382 +++ SEQ ID NO: 02, res. 1383-1397 +++ SEQ ID NO: 02, res. 403-422 +++ SEQ ID NO: 02, res. 1468-1477 +++ SEQ ID NO: 02, res. 474-485 +++ SEQ ID NO: 02, res. 1508-1517 +++__________________________________________________________________________

The subject domains provide Slit domain specific activity or function, such as Slit-specific cell, especially neuron modulating or modulating inhibitory activity, Slit-ligand-binding or binding inhibitory activity. Slit-specific activity or function may be determined by convenient in vitro, cell-based, or in vivo assays: e.g. in vitro binding assays, cell culture assays, in animals (e.g. gene therapy, transgenics, etc.), etc. The binding target may be a natural intracellular binding target, a Slit regulating protein or other regulator that directly modulates Slit activity or its localization; or non-natural binding target such as a specific immune protein such as an antibody, or a Slit specific agent such as those identified in screening assays such as described below. Slit-binding specificity may be assayed by binding equilibrium constants (usually at least about 10.sup.7 M.sup.-1, preferably at least about 10.sup.8 M.sup.-1, more preferably at least about 10.sup.9 M.sup.-1), by the ability of the subject polypeptide to function as negative mutants in Slit-expressing cells, to elicit Slit specific antibody in a heterologous host (e.g a rodent or rabbit), etc.

In one embodiment, the Slit polypeptides are encoded by a nucleic acid comprising SEQ ID NO:01 or a fragment thereof which hybridizes with a full-length strand thereof, preferably under stringent conditions. Such nucleic acids comprise at least 36, preferably at least 72, more preferably at least 144 and most preferably at least 288 nucleotides of SEQ ID NO:01. Demonstrating specific hybridization generally requires stringent conditions, for example, hybridizing in a buffer comprising 30% formamide in 5.times.SSPE (0.18 M NaCl, 0.01 M NaPO.sub.4, pH7.7, 0.001 M EDTA) buffer at a temperature of 42.degree. C. and remaining bound when subject to washing at 42.degree. C. with 0.2.times.SSPE (Conditions I); preferably hybridizing in a buffer comprising 50% formamide in 5.times.SSPE buffer at a temperature of 42.degree. C. and remaining bound when subject to washing at 42.degree. C. with 0.2.times.SSPE buffer at 42.degree. C. (Conditions II). Exemplary nucleic acids which hybridize with a strand of SEQ ID NO:01 are shown in Table 4.

TABLE 4__________________________________________________________________________Exemplary nucleic acids which hybridize with a strand of SEQ ID NO: 01under Conditions I and/or II.Slit Nucleic Acid Hybridization Slit Nucleic Acid Hybridization__________________________________________________________________________SEQ ID NO: 01, nucl. 1-47 + SEQ ID NO: 01, nucl. 1258-1279 + SEQ ID NO: 01, nucl. 58-99 + SEQ ID NO: 01, nucl. 1375-1389 + SEQ ID NO: 01, nucl. 95-138 + SEQ ID NO: 01, nucl. 1581-1595 + SEQ ID NO: 01, nucl. 181-220 + SEQ ID NO: 01, nucl. 1621-1639 + SEQ ID NO: 01, nucl. 261-299 + SEQ ID NO: 01, nucl. 1744-1755 + SEQ ID NO: 01, nucl. 274-315 + SEQ ID NO: 01, nucl. 1951-1969 + SEQ ID NO: 01, nucl. 351-389 + SEQ ID NO: 01, nucl. 2150-2163 + SEQ ID NO: 01, nucl. 450-593 + SEQ ID NO: 01, nucl. 2524-2546 + SEQ ID NO: 01, nucl. 524-546 + SEQ ID NO: 01, nucl. 2761-2780 + SEQ ID NO: 01, nucl. 561-608 + SEQ ID NO: 01, nucl. 2989-2999 + SEQ ID NO: 01, nucl. 689-727 + SEQ ID NO: 01, nucl. 3108-3117 + SEQ ID NO: 01, nucl. 708-737 + SEQ ID NO: 01, nucl. 3338-3351 + SEQ ID NO: 01, nucl. 738-801 + SEQ ID NO: 01, nucl. 3505-3514 + SEQ ID NO: 01, nucl. 805-854 + SEQ ID NO: 01, nucl. 3855-3867 + SEQ ID NO: 01, nucl. 855-907 + SEQ ID NO: 01, nucl. 4010-4025 + SEQ ID NO: 01, nucl. 910-953 + SEQ ID NO: 01, nucl. 4207-4219 + SEQ ID NO: 01, nucl. 1007-1059 + SEQ ID NO: 01, nucl. 4333-4345 + SEQ ID NO: 01, nucl. 1147-1163 + SEQ ID NO: 01, nucl. 4521-4529__________________________________________________________________________

A wide variety of cell types express Robo polypeptides subject to regulation by the disclosed methods, including many neuronal cells, transformed cells, infected (e.g. virus) cells, etc. Ascertaining Robo binding or activation is readily effected by binding assays or cells function assays as disclosed herein or in the cited copending applications. Accordingly, indications for the subject methods encompass a wide variety of cell types and function, including axon outgrowth, tumor cell invasion or migration, etc. The target cell may reside in culture or in situ, i.e. within the natural host. For in situ applications, the compositions are added to a retained physiological fluid such as blood or synovial fluid. For CNS administration, a variety of techniques are available for promoting transfer of the therapeutic across the blood brain barrier including disruption by surgery or injection, drugs which transiently open adhesion contact between CNS vasculature endothelial cells, and compounds which facilitate translocation through such cells. Slit polypeptides may also be amenable to direct injection or infusion, topical, intratracheal/nasal administration e.g. through aerosol, intraocularly, or within/on implants e.g. fibers e.g. collagen, osmotic pumps, grafts comprising appropriately transformed cells, etc. A particular method of administration involves coating, embedding or derivatizing fibers, such as collagen fibers, protein polymers, etc. with therapeutic polypeptides. Other useful approaches are described in Otto et al. (1989) J Neuroscience Research 22, 83-91 and Otto and Unsicker (1990) J Neuroscience 10, 1912-1921. Generally, the amount administered will be empirically determined, typically in the range of about 10 to 1000 .mu.g/kg of the recipient and the concentration will generally be in the range of about 50 to 500 .mu.g/ml in the dose administered. Other additives may be included, such as stabilizers, bactericides, etc. will be present in conventional amounts.

In one embodiment, the invention provides administering the subject Slit polypeptides in combination with a pharmaceutically acceptable excipient such as sterile saline or other medium, gelatin, an oil, etc. to form pharmaceutically acceptable compositions. The compositions and/or compounds may be administered alone or in combination with any convenient carrier, diluent, etc. and such administration may be provided in single or multiple dosages. Useful carriers include solid, semi-solid or liquid media including water and non-toxic organic solvents. In another embodiment, the invention provides the subject compounds in the form of a pro-drug, which can be metabolically converted to the subject compound by the recipient host. A wide variety of pro-drug formulations for polypeptide-based therapeutics are known in the art. The compositions may be provided in any convenient form including tablets, capsules, troches, powders, sprays, creams, etc. As such the compositions, in pharmaceutically acceptable dosage units or in bulk, may be incorporated into a wide variety of containers. For example, dosage units may be included in a variety of containers including capsules, pills, etc. The compositions may be advantageously combined and/or used in combination with other therapeutic or prophylactic agents, different from the subject compounds. In many instances, administration in conjunction with the subject compositions enhances the efficacy of such agents, see e.g. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., 1996, McGraw-Hill.

In another aspect, the invention provides methods of screening for agents which modulate Robo-Slit interactions. These methods generally involve forming a mixture of a Robo-expressing cell, a Slit polypeptide and a candidate agent, and determining the effect of the agent on the amount of Robo expressed by the cell. The methods are amenable to automated, cost-effective high throughput screening of chemical libraries for lead compounds. Identified reagents find use in the pharmaceutical industries for animal and human trials; for example, the reagents may be derivatized and rescreened in vitro and in vivo assays to optimize activity and minimize toxicity for pharmaceutical development. Cell and animal based neural guidance/repulsion assays are described in detail in the experimental section below.

The amino acid sequences of the disclosed vertebrate Slit polypeptides are used to back-translate Slit polypeptide-encoding nucleic acids optimized for selected expression systems (Holler et al. (1993) Gene 136, 323-328; Martin et al. (1995) Gene 154, 150-166) or used to generate degenerate oligonucleotide primers and probes for use in the isolation of natural Slit-encoding nucleic acid sequences ("GCG" software, Genetics Computer Group, Inc, Madison Wis.). Slit-encoding nucleic acids used in Slit-expression vectors and incorporated into recombinant host cells, e.g. for expression and screening, transgenic animals, e.g. for functional studies such as the efficacy of candidate drugs for disease associated with Slit-modulated cell function, etc.

The invention also provides nucleic acid hybridization probes and replication/amplifaction primers having a vertebrate Slit cDNA specific sequence comprising a fragment of a disclosed vertebrate cDNA sequence, and sufficient to effect specific hybridization thereto. Such primers or probes are at least 12, preferably at least 24, more preferably at least 36 and most preferably at least 96 nucleotides in length. Demonstrating specific hybridization generally requires stringent conditions, for example, hybridizing in a buffer comprising 30% formamide in 5.times.SSPE (0.18 M NaCl, 0.01 M NaPO.sub.4, pH7.7, 0.001 M EDTA) buffer at a temperature of 42.degree. C. and remaining bound when subject to washing at 42.degree. C. with 0.2.times.SSPE; preferably hybridizing in a buffer comprising 50% formamide in 5.times.SSPE buffer at a temperature of 42.degree. C. and remaining bound when subject to washing at 42.degree. C. with 0.2.times.SSPE buffer at 42.degree. C. Slit nucleic acids can also be distinguished using alignment algorithms, such as BLASTX (Altschul et al. (1990) Basic Local Alignment Search Tool, J Mol Biol 215, 403-410). In addition, the invention provides nucleic acids having a sequence about 60-70%, preferably about 70-80%, more preferably about 80-90%, more preferably about 90-95%, most preferably about 95-99% similar to a vertebrate Slit sequence disclosed herein as determined by Best Fit analysis using default settings and is other than a natural drosophila Slit sequence, preferably other than a natural invertebrate Slit sequence. In a particular embodiment, the Slit polynucleotide fragments comprise species specific fragments; such fragments are readily discerned from alignments of the disclosed sequences.

The subject nucleic acids are of synthetic/non-natural sequences and/or are recombinant, meaning they comprise a non-natural sequence or a natural sequence joined to nucleotide(s) other than that which it is joined to on a natural chromosome. The subject recombinant nucleic acids comprising the nucleotide sequence of disclosed vertebrate Slit nucleic acids, or fragments thereof, contain such sequence or fragment at a terminus, immediately flanked by (i.e. contiguous with) a sequence other than that which it is joined to on a natural chromosome, or flanked by a native flanking region fewer than 10 kb, preferably fewer than 2 kb, more preferably fewer than 500 bp, which is at a terminus or is immediately flanked by a sequence other than that which it is joined to on a natural chromosome. While the nucleic acids are usually RNA or DNA, it is often advantageous to use nucleic acids comprising other bases or nucleotide analogs to provide modified stability, etc.

The subject nucleic acids find a wide variety of applications including use as translatable transcripts, hybridization probes, PCR primers, diagnostic nucleic acids, etc.; use in detecting the presence of Slit genes and gene transcripts and in detecting or amplifying nucleic acids encoding additional Slit homologs and structural analogs. In diagnosis, Slit hybridization probes find use in identifying wild-type and mutant Slit alleles in clinical and laboratory samples. Mutant alleles are used to generate allele-specific oligonucleotide (ASO) probes for high-throughput clinical diagnoses. In therapy, therapeutic Slit nucleic acids are used to modulate cellular expression or intracellular concentration or availability of active Slit. Exemplary human Slit-1 probes and primers are shown in Table 5 and Table 6.

TABLE 5______________________________________Hybridization Probes for Regions of Human Slit-1.______________________________________Hybridization probe for first leucine SEQ ID NO: 01, nucleotides rich repeat region 82-828 Hybridization probe for second leucine SEQ ID NO: 01, nucleotides rich repeat region 829-1503 Hybridization probe for third leucine SEQ ID NO: 01, nucleotides rich repeat region 1504-2166 Hybridization probe for fourth leucine SEQ ID NO: 01, nucleotides rich repeat region 2167-2751 Hybridization probe for EGF repeats SEQ ID NO: 01, nucleotides one to five 2752-3327 Hybridization probe for the sixth EGF SEQ ID NO: 01, nucleotides repeat and preceding spacer region 3328-3461 Hybridization probe for the 99aa SEQ ID NO: 01, nucleotides spacer/G-loop region 3462-3987 Hybridization probe for EGF repeats SEQ ID NO: 01, nucleotides seven to nine 3988-4341 Hybridization probe for the cysteine SEQ ID NO: 01, nucleotides knot region 4342-4575______________________________________ TABLE 6______________________________________PCR Primers for regions of Human Slit.______________________________________PCR Primers for first Forward: SEQ ID NO: 01, nucleotides leucine rich repeat region 82-111 Reverse: reverse complement of SEQ ID NO: 01, nucleotides 799-828 PCR Primers for second Forward: SEQ ID NO: 01, nucleotides leucine rich repeat region 829-858 Reverse: reverse complement of SEQ ID NO: 01, nucleotides 1474-1503 PCR Primers for third Forward: SEQ ID NO: 01, nucleotides leucine rich repeat region 1504-1533 Reverse: reverse complement of SEQ ID NO: 01, nucleotides 2137-2166 PCR Primers for fourth Forward: SEQ ID NO: 01, nucleotides leucine rich repeat region 2167-2196 Reverse: reverse complement of SEQ ID NO: 01, nucleotides 2722-2751 PCR Primers for EGF Forward: SEQ ID NO: 01, nucleotides repeats one to five 2752-2781 Reverse: reverse complement of SEQ ID NO: 01, nucleotides 3298-3327 PCR Primers for the sixth Forward: SEQ ID NO: 01, nucleotides EGF repeat and preceding 3328-3357 Reverse: reverse complement of spacer region SEQ ID NO: 01, nucleotides 3432-3461 PCR Primers for the 99aa Forward: SEQ ID: 01, nucleotides spacer/G-loop region 3462-3491 Reverse: reverse complement of SEQ ID NO: 01, nucleotides 3958-3987 PCR Primers for EGF Forward: SEQ ID NO: 01, nucleotides repeats seven to nine 3988-4017 Reverse: reverse complement of SEQ ID NO: 01, nucleotides 4312-4341 PCR Primers for the Forward: SEQ ID NO: 01, nucleotides cysteine knot region 4342-4371 Reverse: reverse complement of SEQ ID NO: 01, nucleotides 4546-4575______________________________________

Leucine rich repeats (LRRs) are predicted by comparison with known proteins and by the presence of a leucine rich core sequence. In slit proteins, the LRRs are flanked by conserved sequences referred to as the amino- and carboxy-flanking regions. These flanking regions are found in other known proteins, but only in a few instances are both the amino- and carboxy- flank regions present in a single protein.

The so called "99aa spacer" is actually .about.200 amino acids in the Drosophila protein and 174 amino acids in Human Slit-1. This region shows homology to the G-loops of laminin A chains.

Cysteine knots are dimerisation domains defined by the presence of six cysteine residues between which disulphide bridges form. The only absolutely conserved residues are the six cysteines, and spacing between them is highly variable, apart from between cysteines 2 and 3, and 5 and 6. The glycine between cysteines 2 and 3 is only present in a subset of cysteine knots. Drosophila slit and Human slit-1 both have an extra cysteine after cysteines 5 and 6: this may serve as an intermolecular bond. Human Slit-1 gene displays the overall structure of the Drosophila gene, and amino acid conservation is found along the entire length of the protein (48% homology at the amino acid sequence excluding the signal sequence; see below). The Human gene has an extra LRR between LRR2 and LRR3 of the first set of LRRs; in the third set, the Human gene has an extra LRR between LRR3 and LRR4. The Human gene has two extra EGF repeats, on either side of the seventh EGF repeat in Drosophila slit.

Isolation of Human Slit-1

Searching of the EST database revealed an EST, ab16g10.r1, with homology to the 99aa spacer region of Drosophila slit. This EST was used to probe a Human fetal brain library (Stratagene), and clones for Human slit-1 were isolated.

______________________________________Features of Human Slit Predicted Protein______________________________________Signal sequence SEQ ID NO: 02, residues 7-24 First amino-flanking sequence SEQ ID NO: 02, residues 28-59 First set of Leucine Rich SEQ ID NO: 02, residues 60-179 Repeats (6 repeats) First carboxy-flanking sequence SEQ ID NO: 02, residues 180-276 Second amino-flanking sequence SEQ ID NO: 02, residues 277-308 Second set of Leucine Rich SEQ ID NO: 02, residues 309-434 Repeats (5 repeats) Second carboxy-flanking SEQ ID NO: 02, residues 435-501 sequence Third amino-flanking sequence SEQ ID NO: 02, residues 502-533 Third set of Leucine Rich SEQ ID NO: 02, residues 534-560 Repeats (5 repeats) Third carboxy-flanking sequence SEQ ID NO: 02, residues 661-722 Fourth amino-flanking sequence SEQ ID NO: 02, residues 723-754 Fourth set of Leucine Rich SEQ ID NO: 02, residues 755-855 Repeats (4 repeats) Fourth carboxy-flanking SEQ ID NO: 02, residues 856-917 sequence First EGF repeat SEQ ID NO: 02, residues 918-952 Second EGF repeat SEQ ID NO: 02, residues 953-993 Third EGF repeat SEQ ID NO: 02, residues 994-1031 Fourth EGF repeat SEQ ID NO: 02, residues 1032-1071 Fifth EGF repeat SEQ ID NO: 02, residues 1072-1109 Spacer SEQ ID NO: 02, residues 1110-1116 Sixth EGF repeat SEQ ID NO: 02, residues 1117-1153 "99aa spacer" SEQ ID NO: 02, residues 1155-1329 Seventh EGF repeat SEQ ID NO: 02, residues 1330-1366 Eighth EGF repeat SEQ ID NO: 02, residues 1367-1404 Nineth EGF repeat SEQ ID NO: 02, residues 1405-1447 Cysteine knot motif SEQ ID NO: 02, residues 1448-1525Amino acid identity between Drosophila and Human Slit-1 First amino-flanking sequence 53% First set of Leucine Rich 52% (54%, 67%, NA, 38%, 54%, 50%) Repeats First carboxy-flanking sequence 42% Second amino-flanking sequence 50% Second set of Leucine Rich 60% (54%, 58%, 67%, 71%, 50%) Repeats Second carboxy-flanking 62% sequence Third amino-flanking sequence 56% Third set of Leucine Rich 49% (46%, 46%, 42%, NA, 58%) Repeats Third carboxy-flanking sequence 36% Fourth amino-flanking sequence 53% Fourth set of Leucine Rich 48% (25%, 58%, 46%, 63%) Repeats Fourth carboxy-flanking 63% sequence First EGF repeat 34% Second EGF repeat 46% Third EGF repeat 46% Fourth EGF repeat 35% Fifth EGF repeat 47% Spacer 22% Sixth EGF repeat 40% "99aa spacer" 38% Seventh EGF repeat 11%/NA Eighth EGF repeat 44% Nineth EGF repeat 29%/NA Cysteine knot motif 34%______________________________________ NA: not applicable due to absence of homologous repeat. Figures for individual LLRs are shown in brackets.

The following examplary assay is offered by way of illustration and not by way of limitation:

EXAMPLES

Protocol for Ligand Screening of Transfected COS Cells. I. Prepare the Ligand

Expression Construct: cDNAs encoding targeted Slit polypeptides are tagged with the Fc portion of human IgG and subcloned into a 293 expression vector (pCEP4:In Vitrogen).

Transfection: 293 EBNA cells are transfected (CaPO.sub.4 method) with the Slit expression constructs. After 24 h recovery, transfected cells are selected with G418 (geneticin, 250 ug/ml, Gibco) and hygromycin (200 ug/ml). Once the selection process is complete, cells are maintained in Dulbecco's Modified Eagles medium (DME)/10% FCS under selection.

Preparation of Conditioned Medium: Serum-containing media is replaced with Optimem with glutamax-1 (Gibco) and 300 ng/ml heparin (Sigma), and the cells are conditioned for 3 days. The media is collected and spun at 3,000.times.g for 10 minutes. The supernatant is filtered (0.45 um) and stored with 0.1% azide at 4.degree. C. for no more than 2 weeks.

II. Prepare Truncated Receptor (Positive Control)

Expression Construct: cDNA encoding a corresponding Robo C-terminal deletion mutant comprising the extracellular domain (truncated immediately N-terminal to the transmembrane region) is subcloned into a 293 expression vector (pCEP4:In Vitrogen).

Transfection: 293 EBNA cells are transfected (CaPO.sub.4 method) with the receptor mutant expression construct. After 24 h recovery, transfected cells are selected with G418 (geneticin, 250 ug/ml, Gibco) and hygromycin (200 ug/ml). Once the selection process is complete, cells are maintained in Dulbecco's Modified Eagles medium (DME)/10% FCS under selection.

Preparation of Conditioned Medium: Serum-containing media is replaced with Optimem with glutamax-1 (Gibco) and 300 ng/ml heparin (Sigma), and the cells are conditioned for 3 days. The media is collected and spun at 3,000.times.g for 10 minutes. The supernatant is filtered (0.45 um) and stored with 0.1% azide at 4.degree. C. for no more than 2 weeks.

II. Transfect COS Cells

Seed COS cells (250,000) on 35 mm dishes in 2 ml DME/10% FCS.

18-24 h later, dilute 1 ug of Robo-encoding DNA (cDNA cloned into pMT21 expression vector) into 200 ul serum-free media and add 6 ul of Lipofectamine (Gibco). Incubate this solution at room temperature for 15-45 min.

Wash the cells 2.times.with PBS. Add 800 ul serum-free media to the tube containing the lipid-DNA complexes. Overlay this solution onto the washed cells.

Incubate for 6 h. Stop the reaction by adding 1 ml DMA/20% FCS. Refeed cells. Assay cells 12 hr later.

III. Ligand Binding Assay

Wash plates of transfected COS cells 1.times. with cold PBS (plus Ca/Mg)/1% goat serum Add 1 ml conditioned media neat and incubate 90 min at room temp.

Wash plates 3.times. with PBS (plus Ca/Mg). On the 4th wash, add 1 ml 50% methanol to 1 ml PBS. Then add 1 ml methanol. Evacuate and add 1 ml methanol.

Wash 1.times. with PBS. Wash 1.times.PBS/1% goat serum.

Add secondary antibody (1-to-2,000 anti-human Fc conjugated to alkaline phosphatase (Jackson Lab)) in PBS/1% goat serum. Incubate 30-40 min room temp.

Wash 3.times. with PBS. Wash 1.times. alkaline phosphatase buffer (100 mM Tris-Cl, pH 9.5, 100 mM NaCl, 5 mM MgCl.sub.2. Prepare alkaline phosphatase reagents: 4.5 ul/ml NBT and 3.5 ul/ml BCIP (Gibco) in alkaline phosphatase buffer.

Incubate 10-30 min, quench with 20 mM EDTA in PBS. Cells that have bound Slit polypeptides are visible by the presence of a dark purple reaction product.

In parallel incubations, positive controls are provided by titrating Slit binding with serial dilutions of the mutant receptor conditioned medium.

IV. Results: Binding of Slit to Robo

Cell expressing mammalian Slit polypeptides were shown to bind Robo. No reactivity was observed with control COS cells or with receptor-expressing COS cells in the presence of the secondary antibody but in the absence of the Slit-Fc fusion. Binding was observed to receptor-expression cells using a construct in which a Slit polypeptide is fused directly to alkaline phosphatase, for which a secondary antibody is not required. Receptor deletion mutants titrate the Slit-Robo binding, serving as a positive control for inhibition assays.

Protocol for High Throughput Robo-Slit Binding Assay A. Reagents

Neutralite Avidin: 20 .mu.g/ml in PBS.

Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hour at room temperature.

Assay Buffer: 100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl.sub.2, 1% glycerol, 0.5% NP-40, 50 mM .beta.-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors.

.sup.33 P Robo polypeptide 10.times. stock: 10.sup.-8 -10.sup.-6 M "cold" Robo polypeptide specific Robo domain supplemented with 200,000-250,000 cpm of labeled Robo (Beckman counter). Place in the 4.degree. C. microfridge during screening.

Protease inhibitor cocktail (1000.times.): 10 mg Trypsin Inhibitor (BMB #109894), 10 mg Aprotinin (BMB #236624), 25 mg Benzamidine (Sigma #B-6506), 25 mg Leupeptin (BMB #1017128), 10 mg APMSF (BMB #917575), and 2mM NaVO.sub.3 (Sigma #S-6508) in 10 ml of PBS.

Slit: 10.sup.-7 -10.sup.-5 M biotinylated Slit in PBS.

B. Preparation of Assay Plates

Coat with 120 .mu.l of stock N-Avidin per well overnight at 4.degree. C.

Wash 2 times with 200 .mu.l PBS.

Block with 150 .mu.l of blocking buffer.

Wash 2 times with 200 .mu.l PBS.

C. Assay

Add 40 .mu.l assay buffer/well.

Add 10 .mu.l compound or extract.

Add 10 .mu.l .sup.33 P-Robo (20-25,000 cpm/0.1-10 pmoles/well=10.sup.-9 -10.sup.-7 M final cone).

Shake at 25.degree. C. for 15 minutes.

Incubate additional 45 minutes at 25.degree. C.

Add 40 .mu.M biotinylated Slit (0.1-10 pmoles/40 ul in assay buffer)

Incubate 1 hour at room temperature.

Stop the reaction by washing 4 times with 200 .mu.M PBS.

Add 150 .mu.M scintillation cocktail.

Count in Topcount.

D. Controls for All Assays (Located on Each Plate) a. Non-specific binding b. Soluble (non-biotinylated Slit) at 80% inhibition.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

__________________________________________________________________________# SEQUENCE LISTING - - - - <160> NUMBER OF SEQ ID NOS: 14 - - <210> SEQ ID NO 1 <211> LENGTH: 4758 <212> TYPE: DNA <213> ORGANISM: human <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(4575) - - <400> SEQUENCE: 1 - - atg cgc ggc gtt ggc tgg cag atg ctg tcc ct - #g tcg ctg ggg ttagtg 48 Met Arg Gly Val Gly Trp Gln Met Leu Ser Le - #u Ser Leu Gly Leu Val 1 5 - # 10 - # 15 - - ctg gcg atc ctg aac aag gtg gca ccg cag gc - #g tgc ccg gcg cag tgc 96 Leu Ala Ile Leu Asn Lys Val Ala Pro Gln Al - #a Cys Pro Ala Gln Cys 20 - # 25 - # 30 - - tct tgc tcg ggc agc aca gtg gac tgt cac gg - #g ctg gcg ctg cgc agc 144 Ser Cys Ser Gly Ser Thr Val Asp Cys His Gl - #y Leu Ala Leu Arg Ser 35 - # 40 - # 45 - - gtg ccc agg aat atc ccc cgc aac acc gag ag - #a ctg gat tta aat gga 192 Val Pro Arg Asn Ile Pro Arg Asn Thr Glu Ar - #g Leu Asp Leu Asn Gly 50 - # 55 - # 60 - - aat aac atc aca aga att acg aag aca gat tt - #t gct ggt ctt aga cat 240 Asn Asn Ile Thr Arg Ile Thr Lys Thr Asp Ph - #e Ala Gly Leu Arg His 65 - # 70 - # 75 - # 80 - - cta aga gtt ctt cag ctt atg gag aat aag at - #t agc acc att gaa aga 288 Leu Arg Val Leu Gln Leu Met Glu Asn Lys Il - #e Ser Thr Ile Glu Arg 85 - # 90 - # 95 - - gga gca ttc cag gat ctt aaa gaa cta gag ag - #a ctg cgt tta aac aga 336 Gly Ala Phe Gln Asp Leu Lys Glu Leu Glu Ar - #g Leu Arg Leu Asn Arg 100 - # 105 - # 110 - - aat cac ctt cag ctg ttt cct gag ttg ctg tt - #t ctt ggg act gcg aag 384 Asn His Leu Gln Leu Phe Pro Glu Leu Leu Ph - #e Leu Gly Thr Ala Lys 115 - # 120 - # 125 - - cta tac agg ctt gat ctc agt gaa aac caa at - #t cag gca atc cca agg 432 Leu Tyr Arg Leu Asp Leu Ser Glu Asn Gln Il - #e Gln Ala Ile Pro Arg 130 - # 135 - # 140 - - aaa gct ttc cgt ggg gca gtt gac ata aaa aa - #t ttg caa ctg gat tac 480 Lys Ala Phe Arg Gly Ala Val Asp Ile Lys As - #n Leu Gln Leu Asp Tyr 145 1 - #50 1 - #55 1 -#60 - - aac cag atc agc tgt att gaa gat ggg gca tt - #c agg gct ctc cgggac 528 Asn Gln Ile Ser Cys Ile Glu Asp Gly Ala Ph - #e Arg Ala Leu Arg Asp 165 - # 170 - # 175 - - ctg gaa gtg ctc act ctc aac aat aac aac at - #t act aga ctt tct gtg 576 Leu Glu Val Leu Thr Leu Asn Asn Asn Asn Il - #e Thr Arg Leu Ser Val 180 - # 185 - # 190 - - gca agt ttc aac cat atg cct aaa ctt agg ac - #t ttt cga ctg cat tca 624 Ala Ser Phe Asn His Met Pro Lys Leu Arg Th - #r Phe Arg Leu His Ser 195 - # 200 - # 205 - - aac aac ctg tat tgt gac tgc cac ctg gcc tg - #g ctc tcc gac tgg ctt 672 Asn Asn Leu Tyr Cys Asp Cys His Leu Ala Tr - #p Leu Ser Asp Trp Leu 210 - # 215 - # 220 - - cgc aaa agg cct cgg gtt ggt ctg tac act ca - #g tgt atg ggc ccc tcc 720 Arg Lys Arg Pro Arg Val Gly Leu Tyr Thr Gl - #n Cys Met Gly Pro Ser 225 2 - #30 2 - #35 2 -#40 - - cac ctg aga ggc cat aat gta gcc gag gtt ca - #a aaa cga gaa tttgtc 768 His Leu Arg Gly His Asn Val Ala Glu Val Gl - #n Lys Arg Glu Phe Val 245 - # 250 - # 255 - - tgc agt gat gag gaa gaa ggt cac cag tca tt - #t atg gct cct tct tgt 816 Cys Ser Asp Glu Glu Glu Gly His Gln Ser Ph - #e Met Ala Pro Ser Cys 260 - # 265 - # 270 - - agt gtt ttg cac tgc cct gcc gcc tgt acc tg - #t agc aac aat atc gta 864 Ser Val Leu His Cys Pro Ala Ala Cys Thr Cy - #s Ser Asn Asn Ile Val 275 - # 280 - # 285 - - gac tgt cgt ggg aaa ggt ctc act gag atc cc - #c aca aat ctt cca gag 912 Asp Cys Arg Gly Lys Gly Leu Thr Glu Ile Pr - #o Thr Asn Leu Pro Glu 290 - # 295 - # 300 - - acc atc aca gaa ata cgt ttg gaa cag aac ac - #a atc aaa gtc atc cct 960 Thr Ile Thr Glu Ile Arg Leu Glu Gln Asn Th - #r Ile Lys Val Ile Pro 305 3 - #10 3 - #15 3 -#20 - - cct gga gct ttc tca cca tat aaa aag ctt ag - #a cga att gac ctgagc 1008 Pro Gly Ala Phe Ser Pro Tyr Lys Lys Leu Ar - #g Arg Ile Asp Leu Ser 325 - # 330 - # 335 - - aat aat cag atc tct gaa ctt gca cca gat gc - #t ttc caa gga cta cgc 1056 Asn Asn Gln Ile Ser Glu Leu Ala Pro Asp Al - #a Phe Gln Gly Leu Arg 340 - # 345 - # 350 - - tct ctg aat tca ctt gtc ctc tat gga aat aa - #a atc aca gaa ctc ccc 1104 Ser Leu Asn Ser Leu Val Leu Tyr Gly Asn Ly - #s Ile Thr Glu Leu Pro 355 - # 360 - # 365 - - aaa agt tta ttt gaa gga ctg ttt tcc tta ca - #g ctc cta tta ttg aat 1152 Lys Ser Leu Phe Glu Gly Leu Phe Ser Leu Gl - #n Leu Leu Leu Leu Asn 370 - # 375 - # 380 - - gcc aac aag ata aac tgc ctt cgg gta gat gc - #t ttt cag gat ctc cac 1200 Ala Asn Lys Ile Asn Cys Leu Arg Val Asp Al - #a Phe Gln Asp Leu His 385 3 - #90 3 - #95 4 -#00 - - aac ttg aac ctt ctc tcc cta tat gac aac aa - #g ctt cag acc atcgcc 1248 Asn Leu Asn Leu Leu Ser Leu Tyr Asp Asn Ly - #s Leu Gln Thr Ile Ala 405 - # 410 - # 415 - - aag ggg acc ttt tca cct ctt cgg gcc att ca - #a act atg cat ttg gcc 1296 Lys Gly Thr Phe Ser Pro Leu Arg Ala Ile Gl - #n Thr Met His Leu Ala 420 - # 425 - # 430 - - cag aac ccc ttt att tgt gac tgc cat ctc aa - #g tgg cta gcg gat tat 1344 Gln Asn Pro Phe Ile Cys Asp Cys His Leu Ly - #s Trp Leu Ala Asp Tyr 435 - # 440 - # 445 - - ctc cat acc aac ccg att gag acc agt ggt gc - #c cgt tgc acc agc ccc 1392 Leu His Thr Asn Pro Ile Glu Thr Ser Gly Al - #a Arg Cys Thr Ser Pro 450 - # 455 - # 460 - - cgc cgc ctg gca aac aaa aga att gga cag at - #c aaa agc aag aaa ttc 1440 Arg Arg Leu Ala Asn Lys Arg Ile Gly Gln Il - #e Lys Ser Lys Lys Phe 465 4 - #70 4 - #75 4 -#80 - - cgt tgt tca ggt aca gaa gat tat cga tca aa - #a tta agt gga gactgc 1488 Arg Cys Ser Gly Thr Glu Asp Tyr Arg Ser Ly - #s Leu Ser Gly Asp Cys 485 - # 490 - # 495 - - ttt gcg gat ctg gct tgc cct gaa aag tgt cg - #c tgt gaa gga acc aca 1536 Phe Ala Asp Leu Ala Cys Pro Glu Lys Cys Ar - #g Cys Glu Gly Thr Thr 500 - # 505 - # 510 - - gta gat tgc tct aat caa aag ctc aac aaa at - #c ccg gag cac att ccc 1584 Val Asp Cys Ser Asn Gln Lys Leu Asn Lys Il - #e Pro Glu His Ile Pro 515 - # 520 - # 525 - - cag tac act gca gag ttg cgt ctc aat aat aa - #t gaa ttt acc gtg ttg 1632 Gln Tyr Thr Ala Glu Leu Arg Leu Asn Asn As - #n Glu Phe Thr Val Leu 530 - # 535 - # 540 - - gaa gcc aca gga atc ttt aag aaa ctt cct ca - #a tta cgt aaa ata aac 1680 Glu Ala Thr Gly Ile Phe Lys Lys Leu Pro Gl - #n Leu Arg Lys Ile Asn 545 5 - #50 5 - #55 5 -#60 - - ttt agc aac aat aag atc aca gat att gag ga - #g gga gca ttt gaagga 1728 Phe Ser Asn Asn Lys Ile Thr Asp Ile Glu Gl - #u Gly Ala Phe Glu Gly 565 - # 570 - # 575 - - gca tct ggt gta aat gaa ata ctt ctt acg ag - #t aat cgt ttg gaa aat 1776 Ala Ser Gly Val Asn Glu Ile Leu Leu Thr Se - #r Asn Arg Leu Glu Asn 580 - # 585 - # 590 - - gtg cag cat aag atg ttc aag gga ttg gaa ag - #c ctc aaa act ttg atg 1824 Val Gln His Lys Met Phe Lys Gly Leu Glu Se - #r Leu Lys Thr Leu Met 595 - # 600 - # 605 - - ttg aga agc aat cga ata acc tgt gtg ggg aa - #t gac agt ttc ata gga 1872 Leu Arg Ser Asn Arg Ile Thr Cys Val Gly As - #n Asp Ser Phe Ile Gly 610 - # 615 - # 620 - - ctc agt tct gtg cgt ttg ctt tct ttg tat ga - #t aat caa att act aca 1920 Leu Ser Ser Val Arg Leu Leu Ser Leu Tyr As - #p Asn Gln Ile Thr Thr 625 6 - #30 6 - #35 6 -#40 - - gtt gca cca ggg gca ttt gat act ctc cat tc - #t tta tct act ctaaac 1968 Val Ala Pro Gly Ala Phe Asp Thr Leu His Se - #r Leu Ser Thr Leu Asn 645 - # 650 - # 655 - - ctc ttg gcc aat cct ttt aac tgt aac tgc ta - #c ctg gct tgg ttg gga 2016 Leu Leu Ala Asn Pro Phe Asn Cys Asn Cys Ty - #r Leu Ala Trp Leu Gly 660 - # 665 - # 670 - - gag tgg ctg aga aag aag aga att gtc acg gg - #a aat cct aga tgt caa 2064 Glu Trp Leu Arg Lys Lys Arg Ile Val Thr Gl - #y Asn Pro Arg Cys Gln 675 - # 680 - # 685 - - aaa cca tac ttc ctg aaa gaa ata ccc atc ca - #g gat gtg gcc att cag 2112 Lys Pro Tyr Phe Leu Lys Glu Ile Pro Ile Gl - #n Asp Val Ala Ile Gln 690 - # 695 - # 700 - - gac ttc act tgt gat gac gga aat gat gac aa - #t agt tgc tcc cca ctt 2160 Asp Phe Thr Cys Asp Asp Gly Asn Asp Asp As - #n Ser Cys Ser Pro Leu 705 7 - #10 7 - #15 7 -#20 - - tct cgc tgt cct act gaa tgt act tgc ttg ga - #t aca gtc gtc cgatgt 2208 Ser Arg Cys Pro Thr Glu Cys Thr Cys Leu As - #p Thr Val Val Arg Cys 725 - # 730 - # 735 - - agc aac aag ggt ttg aag gtc ttg ccg aaa gg - #t att cca aga gat gtc 2256 Ser Asn Lys Gly Leu Lys Val Leu Pro Lys Gl - #y Ile Pro Arg Asp Val 740 - # 745 - # 750 - - aca gag ttg tat ctg gat gga aac caa ttt ac - #a ctg gtt ccc aag gaa 2304 Thr Glu Leu Tyr Leu Asp Gly Asn Gln Phe Th - #r Leu Val Pro Lys Glu 755 - # 760 - # 765 - - ctc tcc aac tac aaa cat tta aca ctt ata ga - #c tta agt aac aac aga 2352 Leu Ser Asn Tyr Lys His Leu Thr Leu Ile As - #p Leu Ser Asn Asn Arg 770 - # 775 - # 780 - - ata agc acg ctt tct aat cag agc ttc agc aa - #c atg acc cag ctc ctc 2400 Ile Ser Thr Leu Ser Asn Gln Ser Phe Ser As - #n Met Thr Gln Leu Leu 785 7 - #90 7 - #95 8 -#00 - - acc tta att ctt agt tac aac cgt ctg aga tg - #t att cct cct cgcacc 2448 Thr Leu Ile Leu Ser Tyr Asn Arg Leu Arg Cy - #s Ile Pro Pro Arg Thr 805 - # 810 - # 815 - - ttt gat gga tta aag tct ctt cga tta ctt tc - #t cta cat gga aat gac 2496 Phe Asp Gly Leu Lys Ser Leu Arg Leu Leu Se - #r Leu His Gly Asn Asp 820 - # 825 - # 830 - - att tct gtt gtg cct gaa ggt gct ttc aat ga - #t ctt tct gca tta tca 2544 Ile Ser Val Val Pro Glu Gly Ala Phe Asn As - #p Leu Ser Ala Leu Ser 835 - # 840 - # 845 - - cat cta gca att gga gcc aac cct ctt tac tg - #t gat tgt aac atg cag 2592 His Leu Ala Ile Gly Ala Asn Pro Leu Tyr Cy - #s Asp Cys Asn Met Gln 850 - # 855 - # 860 - - tgg tta tcc gac tgg gtg aag tcg gaa tat aa - #g gag cct gga att gct 2640 Trp Leu Ser Asp Trp Val Lys Ser Glu Tyr Ly - #s Glu Pro Gly Ile Ala 865 8 - #70 8 - #75 8 -#80 - - cgt tgt gct ggt cct gga gaa atg gca gat aa - #a ctt tta ctc acaact 2688 Arg Cys Ala Gly Pro Gly Glu Met Ala Asp Ly - #s Leu Leu Leu Thr Thr - - 885 - # 890 - # 895 ccc tcc aaa aaa ttt acc tgt caa ggt cct gt - #g gat gtc aat att cta2736 Pro Ser Lys Lys Phe Thr Cys Gln Gly Pro Va - #l Asp Val Asn Ile Leu 900 - # 905 - # 910 - - gct aag tgt aac ccc tgc cta tca aat ccg tg - #t aaa aat gat ggc aca 2784 Ala Lys Cys Asn Pro Cys Leu Ser Asn Pro Cy - #s Lys Asn Asp Gly Thr 915 - # 920 - # 925 - - tgt aat agt gat cca gtt gac ttt tac cga tg - #c acc tgt cca tat ggt 2832 Cys Asn Ser Asp Pro Val Asp Phe Tyr Arg Cy - #s Thr Cys Pro Tyr Gly 930 - # 935 - # 940 - - ttc aag ggg cag gac tgt gat gtc cca att ca - #t gcc tgc atc agt aac 2880 Phe Lys Gly Gln Asp Cys Asp Val Pro Ile Hi - #s Ala Cys Ile Ser Asn 945 9 - #50 9 - #55 9 -#60 - - cca tgt aaa cat gga gga act tgc cac tta aa - #g gaa gga gaa gaagat 2928 Pro Cys Lys His Gly Gly Thr Cys His Leu Ly - #s Glu Gly Glu Glu Asp 965 - # 970 - # 975 - - gga ttc tgg tgt att tgt gct gat gga ttt ga - #a gga gaa aat tgt gaa 2976 Gly Phe Trp Cys Ile Cys Ala Asp Gly Phe Gl - #u Gly Glu Asn Cys Glu 980 - # 985 - # 990 - - gtc aac gtt gat gat tgt gaa gat aat gac tg - #t gaa aat aat tct aca 3024 Val Asn Val Asp Asp Cys Glu Asp Asn Asp Cy - #s Glu Asn Asn Ser Thr 995 - # 1000 - # 1005 - - tgt gtc gat ggc att aat aac tac aca tgc ct - #t tgc cca cct gag tat 3072 Cys Val Asp Gly Ile Asn Asn Tyr Thr Cys Le - #u Cys Pro Pro Glu Tyr 1010 - # 1015 - # 1020 - - aca ggt gag ttg tgt gag gag aag ctg gac tt - #c tgt gcc cag gac ctg 3120 Thr Gly Glu Leu Cys Glu Glu Lys Leu Asp Ph - #e Cys Ala Gln Asp Leu 1025 1030 - # 1035 - # 1040 - - aac ccc tgc cag cac gat tca aag tgc atc ct - #a act cca aag gga ttc 3168 Asn Pro Cys Gln His Asp Ser Lys Cys Ile Le - #u Thr Pro Lys Gly Phe 1045 - # 1050 - # 1055 - - aaa tgt gac tgc aca cca ggg tac gta ggt ga - #a cac tgc gac atc gat 3216 Lys Cys Asp Cys Thr Pro Gly Tyr Val Gly Gl - #u His Cys Asp Ile Asp 1060 - # 1065 - # 1070 - - ttt gac gac tgc caa gac aac aag tgt aaa aa - #c gga gcc cac tgc aca 3264 Phe Asp Asp Cys Gln Asp Asn Lys Cys Lys As - #n Gly Ala His Cys Thr 1075 - # 1080 - # 1085 - - gat gca gtg aac ggc tat acg tgc ata tgc cc - #c gaa ggt tac agt ggc 3312 Asp Ala Val Asn Gly Tyr Thr Cys Ile Cys Pr - #o Glu Gly Tyr Ser Gly 1090 - # 1095 - # 1100 - - ttg ttc tgt gag ttt tct cca ccc atg gtc ct - #c cct cgt acc agc ccc 3360 Leu Phe Cys Glu Phe Ser Pro Pro Met Val Le - #u Pro Arg Thr Ser Pro 1105 1110 - # 1115 - # 1120 - - tgt gat aat ttt gat tgt cag aat gga gct ca - #g tgt atc gtc aga ata 3408 Cys Asp Asn Phe Asp Cys Gln Asn Gly Ala Gl - #n Cys Ile Val Arg Ile 1125 - # 1130 - # 1135 - - aat gag cca ata tgt cag tgt ttg cct ggc ta - #t cag gga gaa aag tgt 3456 Asn Glu Pro Ile Cys Gln Cys Leu Pro Gly Ty - #r Gln Gly Glu Lys Cys 1140 - # 1145 - # 1150 - - gaa aaa ttg gtt agt gtg aat ttt ata aac aa - #a gag tct tat ctt cag 3504 Glu Lys Leu Val Ser Val Asn Phe Ile Asn Ly - #s Glu Ser Tyr Leu Gln 1155 - # 1160 - # 1165 - - att cct tca gcc aag gtt cgg cct cag acg aa - #c ata aca ctt cag att 3552 Ile Pro Ser Ala Lys Val Arg Pro Gln Thr As - #n Ile Thr Leu Gln Ile 1170 - # 1175 - # 1180 - - gcc aca gat gaa gac agc gga atc ctc ctg ta - #t aag ggt gac aaa gac 3600 Ala Thr Asp Glu Asp Ser Gly Ile Leu Leu Ty - #r Lys Gly Asp Lys Asp 1185 1190 - # 1195 - # 1200 - - cat atc gcg gta gaa ctc tat cgg ggg cgt gt - #t cgt gcc agc tat gac 3648 His Ile Ala Val Glu Leu Tyr Arg Gly Arg Va - #l Arg Ala Ser Tyr Asp 1205 - # 1210 - # 1215 - - acc ggc tct cat cca gct tct gcc att tac ag - #t gtg gag aca atc aat 3696 Thr Gly Ser His Pro Ala Ser Ala Ile Tyr Se - #r Val Glu Thr Ile Asn 1220 - # 1225 - # 1230 - - gat gga aac ttc cac att gtg gaa cta ctt gc - #c ttg gat cag agt ctc 3744 Asp Gly Asn Phe His Ile Val Glu Leu Leu Al - #a Leu Asp Gln Ser Leu 1235 - # 1240 - # 1245 - - tct ttg tcc gtg gat ggt ggg aac ccc aaa at - #c atc act aac ttg tca 3792 Ser Leu Ser Val Asp Gly Gly Asn Pro Lys Il - #e Ile Thr Asn Leu Ser 1250 - # 1255 - # 1260 - - aag cag tcc act ctg aat ttt gac tct cca ct - #c tat gta gga ggc atg 3840 Lys Gln Ser Thr Leu Asn Phe Asp Ser Pro Le - #u Tyr Val Gly Gly Met 1265 1270 - # 1275 - # 1280 - - cca ggg aag agt aac gtg gca tct ctg cgc ca - #g gcc cct ggg cag aac 3888 Pro Gly Lys Ser Asn Val Ala Ser Leu Arg Gl - #n Ala Pro Gly Gln Asn 1285 - # 1290 - # 1295 - - gga acc agc ttc cac ggc tgc atc cgg aac ct - #t tac atc aac agt gag 3936 Gly Thr Ser Phe His Gly Cys Ile Arg Asn Le - #u Tyr Ile Asn Ser Glu 1300 - # 1305 - # 1310 - - ctg cag gac ttc cag aag gtg ccg atg caa ac - #a ggc att ttg cct ggc 3984 Leu Gln Asp Phe Gln Lys Val Pro Met Gln Th - #r Gly Ile Leu Pro Gly 1315 - # 1320 - # 1325 - - tgt gag cca tgc cac aag aag gtg tgt gcc ca - #t ggc aca tgc cag ccc 4032 Cys Glu Pro Cys His Lys Lys Val Cys Ala Hi - #s Gly Thr Cys Gln Pro 1330 - # 1335 - # 1340 - - agc agc cag gca ggc ttc acc tgc gag tgc ca - #g gaa gga tgg atg ggg 4080 Ser Ser Gln Ala Gly Phe Thr Cys Glu Cys Gl - #n Glu Gly Trp Met Gly 1345 1350 - # 1355 - # 1360 - - ccc ctc tgt gac caa cgg acc aat gac cct tg - #c ctt gga aat aaa tgc 4128 Pro Leu Cys Asp Gln Arg Thr Asn Asp Pro Cy - #s Leu Gly Asn Lys Cys 1365 - # 1370 - # 1375 - - gta cat ggc acc tgc ttg ccc atc aat gcg tt - #c tcc tac agc tgt aag 4176 Val His Gly Thr Cys Leu Pro Ile Asn Ala Ph - #e Ser Tyr Ser Cys Lys 1380 - # 1385 - # 1390 - - tgc ttg gag ggc cat gga ggt gtc ctc tgt ga - #t gaa gag gag gat ctg 4224 Cys Leu Glu Gly His Gly Gly Val Leu Cys As - #p Glu Glu Glu Asp Leu 1395 - # 1400 - # 1405 - - ttt aac cca tgc cag gcg atc aag tgc aag ca - #t ggg aag tgc agg ctt 4272 Phe Asn Pro Cys Gln Ala Ile Lys Cys Lys Hi - #s Gly Lys Cys Arg Leu 1410 - # 1415 - # 1420 - - tca ggt ctg ggg cag ccc tac tgt gaa tgc ag - #c agt gga tac acg ggg 4320 Ser Gly Leu Gly Gln Pro Tyr Cys Glu Cys Se - #r Ser Gly Tyr Thr Gly 1425 1430 - # 1435 - # 1440 - - gac agc tgt gat cga gaa atc tct tgt cga gg - #g gaa agg ata aga gat 4368 Asp Ser Cys Asp Arg Glu Ile Ser Cys Arg Gl - #y Glu Arg Ile Arg Asp 1445 - # 1450 - # 1455 - - tat tac caa aag cag cag ggc tat gct gct tg - #c caa aca acc aag aag 4416 Tyr Tyr Gln Lys Gln Gln Gly Tyr Ala Ala Cy - #s Gln Thr Thr Lys Lys 1460 - # 1465 - # 1470 - - gtg tcc cga tta gag tgc aga ggt ggg tgt gc - #a gga ggg cag tgc tgt 4464 Val Ser Arg Leu Glu Cys Arg Gly Gly Cys Al - #a Gly Gly Gln Cys Cys 1475 - # 1480 - # 1485 - - gga ccg ctg agg agc aag cgg cgg aaa tac tc - #t ttc gaa tgc act gac 4512 Gly Pro Leu Arg Ser Lys Arg Arg Lys Tyr Se - #r Phe Glu Cys Thr Asp 1490 - # 1495 - # 1500 - - ggc tcc tcc ttt gtg gac gag gtt gag aaa gt - #g gtg aag tgc ggc tgt 4560 Gly Ser Ser Phe Val Asp Glu Val Glu Lys Va - #l Val Lys Cys Gly Cys 1505 1510 - # 1515 - # 1520 - - acg agg tgt gtg tcc taaacacact cccggcagct ctgtctttg - #g aaaaggttgt 4615 Thr Arg Cys Val Ser 1525 - - atacttcttg accatgtggg actaatgaat gcttcatagt ggaaatattt ga -#aatatatt 4675 - - gtaaaataca gaacagactt atttttatta tgagaataaa gacttttttt ct -#gcatttgg 4735 - - aaaaaaaaaa aaaaaaaact cga - # - # 4758 - - - - <210> SEQ ID NO 2 <211> LENGTH: 1525 <212> TYPE: PRT <213> ORGANISM: human - - <400> SEQUENCE: 2 - - Met Arg Gly Val Gly Trp Gln Met Leu Ser Le - #u Ser Leu Gly Leu Val 1 5 - # 10 - # 15 - - Leu Ala Ile Leu Asn Lys Val Ala Pro Gln Al - #a Cys Pro Ala Gln Cys 20 - # 25 - # 30 - - Ser Cys Ser Gly Ser Thr Val Asp Cys His Gl - #y Leu Ala Leu Arg Ser 35 - # 40 - # 45 - - Val Pro Arg Asn Ile Pro Arg Asn Thr Glu Ar - #g Leu Asp Leu Asn Gly 50 - # 55 - # 60 - - Asn Asn Ile Thr Arg Ile Thr Lys Thr Asp Ph - #e Ala Gly Leu Arg His 65 - # 70 - # 75 - # 80 - - Leu Arg Val Leu Gln Leu Met Glu Asn Lys Il - #e Ser Thr Ile Glu Arg 85 - # 90 - # 95 - - Gly Ala Phe Gln Asp Leu Lys Glu Leu Glu Ar - #g Leu Arg Leu Asn Arg 100 - # 105 - # 110 - - Asn His Leu Gln Leu Phe Pro Glu Leu Leu Ph - #e Leu Gly Thr Ala Lys 115 - # 120 - # 125 - - Leu Tyr Arg Leu Asp Leu Ser Glu Asn Gln Il - #e Gln Ala Ile Pro Arg 130 - # 135 - # 140 - - Lys Ala Phe Arg Gly Ala Val Asp Ile Lys As - #n Leu Gln Leu Asp Tyr 145 1 - #50 1 - #55 1 -#60 - - Asn Gln Ile Ser Cys Ile Glu Asp Gly Ala Ph - #e Arg Ala Leu ArgAsp 165 - # 170 - # 175 - - Leu Glu Val Leu Thr Leu Asn Asn Asn Asn Il - #e Thr Arg Leu Ser Val 180 - # 185 - # 190 - - Ala Ser Phe Asn His Met Pro Lys Leu Arg Th - #r Phe Arg Leu His Ser 195 - # 200 - # 205 - - Asn Asn Leu Tyr Cys Asp Cys His Leu Ala Tr - #p Leu Ser Asp Trp Leu 210 - # 215 - # 220 - - Arg Lys Arg Pro Arg Val Gly Leu Tyr Thr Gl - #n Cys Met Gly Pro Ser 225 2 - #30 2 - #35 2 -#40 - - His Leu Arg Gly His Asn Val Ala Glu Val Gl - #n Lys Arg Glu PheVal 245 - # 250 - # 255 - - Cys Ser Asp Glu Glu Glu Gly His Gln Ser Ph - #e Met Ala Pro Ser Cys 260 - # 265 - # 270 - - Ser Val Leu His Cys Pro Ala Ala Cys Thr Cy - #s Ser Asn Asn Ile Val 275 - # 280 - # 285 - - Asp Cys Arg Gly Lys Gly Leu Thr Glu Ile Pr - #o Thr Asn Leu Pro Glu 290 - # 295 - # 300 - - Thr Ile Thr Glu Ile Arg Leu Glu Gln Asn Th - #r Ile Lys Val Ile Pro 305 3 - #10 3 - #15 3 -#20 - - Pro Gly Ala Phe Ser Pro Tyr Lys Lys Leu Ar - #g Arg Ile Asp LeuSer 325 - # 330 - # 335 - - Asn Asn Gln Ile Ser Glu Leu Ala Pro Asp Al - #a Phe Gln Gly Leu Arg 340 - # 345 - # 350 - - Ser Leu Asn Ser Leu Val Leu Tyr Gly Asn Ly - #s Ile Thr Glu Leu Pro 355 - # 360 - # 365 - - Lys Ser Leu Phe Glu Gly Leu Phe Ser Leu Gl - #n Leu Leu Leu Leu Asn 370 - # 375 - # 380 - - Ala Asn Lys Ile Asn Cys Leu Arg Val Asp Al - #a Phe Gln Asp Leu His 385 3 - #90 3 - #95 4 -#00 - - Asn Leu Asn Leu Leu Ser Leu Tyr Asp Asn Ly - #s Leu Gln Thr IleAla 405 - # 410 - # 415 - - Lys Gly Thr Phe Ser Pro Leu Arg Ala Ile Gl - #n Thr Met His Leu Ala 420 - # 425 - # 430 - - Gln Asn Pro Phe Ile Cys Asp Cys His Leu Ly - #s Trp Leu Ala Asp Tyr 435 - # 440 - # 445 - - Leu His Thr Asn Pro Ile Glu Thr Ser Gly Al - #a Arg Cys Thr Ser Pro 450 - # 455 - # 460 - - Arg Arg Leu Ala Asn Lys Arg Ile Gly Gln Il - #e Lys Ser Lys Lys Phe 465 4 - #70 4 - #75 4 -#80 - - Arg Cys Ser Gly Thr Glu Asp Tyr Arg Ser Ly - #s Leu Ser Gly AspCys 485 - # 490 - # 495 - - Phe Ala Asp Leu Ala Cys Pro Glu Lys Cys Ar - #g Cys Glu Gly Thr Thr 500 - # 505 - # 510 - - Val Asp Cys Ser Asn Gln Lys Leu Asn Lys Il - #e Pro Glu His Ile Pro 515 - # 520 - # 525 - - Gln Tyr Thr Ala Glu Leu Arg Leu Asn Asn As - #n Glu Phe Thr Val Leu 530 - # 535 - # 540 - - Glu Ala Thr Gly Ile Phe Lys Lys Leu Pro Gl - #n Leu Arg Lys Ile Asn 545 5 - #50 5 - #55 5 -#60 - - Phe Ser Asn Asn Lys Ile Thr Asp Ile Glu Gl - #u Gly Ala Phe GluGly 565 - # 570 - # 575 - - Ala Ser Gly Val Asn Glu Ile Leu Leu Thr Se - #r Asn Arg Leu Glu Asn 580 - # 585 - # 590 - - Val Gln His Lys Met Phe Lys Gly Leu Glu Se - #r Leu Lys Thr Leu Met 595 - # 600 - # 605 - - Leu Arg Ser Asn Arg Ile Thr Cys Val Gly As - #n Asp Ser Phe Ile Gly 610 - # 615 - # 620 - - Leu Ser Ser Val Arg Leu Leu Ser Leu Tyr As - #p Asn Gln Ile Thr Thr 625 6 - #30 6 - #35 6 -#40 - - Val Ala Pro Gly Ala Phe Asp Thr Leu His Se - #r Leu Ser Thr LeuAsn 645 - # 650 - # 655 - - Leu Leu Ala Asn Pro Phe Asn Cys Asn Cys Ty - #r Leu Ala Trp Leu Gly 660 - # 665 - # 670 - - Glu Trp Leu Arg Lys Lys Arg Ile Val Thr Gl - #y Asn Pro Arg Cys Gln 675 - # 680 - # 685 - - Lys Pro Tyr Phe Leu Lys Glu Ile Pro Ile Gl - #n Asp Val Ala Ile Gln 690 - # 695 - # 700 - - Asp Phe Thr Cys Asp Asp Gly Asn Asp Asp As - #n Ser Cys Ser Pro Leu 705 7 - #10 7 - #15 7 -#20 - - Ser Arg Cys Pro Thr Glu Cys Thr Cys Leu As - #p Thr Val Val ArgCys 725 - # 730 - # 735 - - Ser Asn Lys Gly Leu Lys Val Leu Pro Lys Gl - #y Ile Pro Arg Asp Val 740 - # 745 - # 750 - - Thr Glu Leu Tyr Leu Asp Gly Asn Gln Phe Th - #r Leu Val Pro Lys Glu 755 - # 760 - # 765 - - Leu Ser Asn Tyr Lys His Leu Thr Leu Ile As - #p Leu Ser Asn Asn Arg 770 - # 775 - # 780 - - Ile Ser Thr Leu Ser Asn Gln Ser Phe Ser As - #n Met Thr Gln Leu Leu 785 7 - #90 7 - #95 8 -#00 - - Thr Leu Ile Leu Ser Tyr Asn Arg Leu Arg Cy - #s Ile Pro Pro ArgThr 805 - # 810 - # 815 - - Phe Asp Gly Leu Lys Ser Leu Arg Leu Leu Se - #r Leu His Gly Asn Asp 820 - # 825 - # 830 - - Ile Ser Val Val Pro Glu Gly Ala Phe Asn As - #p Leu Ser Ala Leu Ser 835 - # 840 - # 845 - - His Leu Ala Ile Gly Ala Asn Pro Leu Tyr Cy - #s Asp Cys Asn Met Gln 850 - # 855 - # 860 - - Trp Leu Ser Asp Trp Val Lys Ser Glu Tyr Ly - #s Glu Pro Gly Ile Ala 865 8 - #70 8 - #75 8 -#80 - - Arg Cys Ala Gly Pro Gly Glu Met Ala Asp Ly - #s Leu Leu Leu ThrThr 885 - # 890 - # 895 - - Pro Ser Lys Lys Phe Thr Cys Gln Gly Pro Va - #l Asp Val Asn Ile Leu 900 - # 905 - # 910 - - Ala Lys Cys Asn Pro Cys Leu Ser Asn Pro Cy - #s Lys Asn Asp Gly Thr 915 - # 920 - # 925 - - Cys Asn Ser Asp Pro Val Asp Phe Tyr Arg Cy - #s Thr Cys Pro Tyr Gly 930 - # 935 - # 940 - - Phe Lys Gly Gln Asp Cys Asp Val Pro Ile Hi - #s Ala Cys Ile Ser Asn 945 9 - #50 9 - #55 9 -#60 - - Pro Cys Lys His Gly Gly Thr Cys His Leu Ly - #s Glu Gly Glu GluAsp 965 - # 970 - # 975 - - Gly Phe Trp Cys Ile Cys Ala Asp Gly Phe Gl - #u Gly Glu Asn Cys Glu 980 - # 985 - # 990 - - Val Asn Val Asp Asp Cys Glu Asp Asn Asp Cy - #s Glu Asn Asn Ser Thr 995 - # 1000 - # 1005 - - Cys Val Asp Gly Ile Asn Asn Tyr Thr Cys Le - #u Cys Pro Pro Glu Tyr 1010 - # 1015 - # 1020 - - Thr Gly Glu Leu Cys Glu Glu Lys Leu Asp Ph - #e Cys Ala Gln Asp Leu 1025 1030 - # 1035 - # 1040 - - Asn Pro Cys Gln His Asp Ser Lys Cys Ile Le - #u Thr Pro Lys Gly Phe 1045 - # 1050 - # 1055 - - Lys Cys Asp Cys Thr Pro Gly Tyr Val Gly Gl - #u His Cys Asp Ile Asp 1060 - # 1065 - # 1070 - - Phe Asp Asp Cys Gln Asp Asn Lys Cys Lys As - #n Gly Ala His Cys Thr 1075 - # 1080 - # 1085 - - Asp Ala Val Asn Gly Tyr Thr Cys Ile Cys Pr - #o Glu Gly Tyr Ser Gly 1090 - # 1095 - # 1100 - - Leu Phe Cys Glu Phe Ser Pro Pro Met Val Le - #u Pro Arg Thr Ser Pro 1105 1110 - # 1115 - # 1120 - - Cys Asp Asn Phe Asp Cys Gln Asn Gly Ala Gl - #n Cys Ile Val Arg Ile 1125 - # 1130 - # 1135 - - Asn Glu Pro Ile Cys Gln Cys Leu Pro Gly Ty - #r Gln Gly Glu Lys Cys 1140 - # 1145 - # 1150 - - Glu Lys Leu Val Ser Val Asn Phe Ile Asn Ly - #s Glu Ser Tyr Leu Gln 1155 - # 1160 - # 1165 - - Ile Pro Ser Ala Lys Val Arg Pro Gln Thr As - #n Ile Thr Leu Gln Ile 1170 - # 1175 - # 1180 - - Ala Thr Asp Glu Asp Ser Gly Ile Leu Leu Ty - #r Lys Gly Asp Lys Asp 1185 1190 - # 1195 - # 1200 - - His Ile Ala Val Glu Leu Tyr Arg Gly Arg Va - #l Arg Ala Ser Tyr Asp 1205 - # 1210 - # 1215 - - Thr Gly Ser His Pro Ala Ser Ala Ile Tyr Se - #r Val Glu Thr Ile Asn 1220 - # 1225 - # 1230 - - Asp Gly Asn Phe His Ile Val Glu Leu Leu Al - #a Leu Asp Gln Ser Leu 1235 - # 1240 - # 1245 - - Ser Leu Ser Val Asp Gly Gly Asn Pro Lys Il - #e Ile Thr Asn Leu Ser 1250 - # 1255 - # 1260 - - Lys Gln Ser Thr Leu Asn Phe Asp Ser Pro Le - #u Tyr Val Gly Gly Met 1265 1270 - # 1275 - # 1280 - - Pro Gly Lys Ser Asn Val Ala Ser Leu Arg Gl - #n Ala Pro Gly Gln Asn 1285 - # 1290 - # 1295 - - Gly Thr Ser Phe His Gly Cys Ile Arg Asn Le - #u Tyr Ile Asn Ser Glu 1300 - # 1305 - # 1310 - - Leu Gln Asp Phe Gln Lys Val Pro Met Gln Th - #r Gly Ile Leu Pro Gly 1315 - # 1320 - # 1325 - - Cys Glu Pro Cys His Lys Lys Val Cys Ala Hi - #s Gly Thr Cys Gln Pro 1330 - # 1335 - # 1340 - - Ser Ser Gln Ala Gly Phe Thr Cys Glu Cys Gl - #n Glu Gly Trp Met Gly 1345 1350 - # 1355 - # 1360 - - Pro Leu Cys Asp Gln Arg Thr Asn Asp Pro Cy - #s Leu Gly Asn Lys Cys 1365 - # 1370 - # 1375 - - Val His Gly Thr Cys Leu Pro Ile Asn Ala Ph - #e Ser Tyr Ser Cys Lys 1380 - # 1385 - # 1390 - - Cys Leu Glu Gly His Gly Gly Val Leu Cys As - #p Glu Glu Glu Asp Leu 1395 - # 1400 - # 1405 - - Phe Asn Pro Cys Gln Ala Ile Lys Cys Lys Hi - #s Gly Lys Cys Arg Leu 1410 - # 1415 - # 1420 - - Ser Gly Leu Gly Gln Pro Tyr Cys Glu Cys Se - #r Ser Gly Tyr Thr Gly 1425 1430 - # 1435 - # 1440 - - Asp Ser Cys Asp Arg Glu Ile Ser Cys Arg Gl - #y Glu Arg Ile Arg Asp 1445 - # 1450 - # 1455 - - Tyr Tyr Gln Lys Gln Gln Gly Tyr Ala Ala Cy - #s Gln Thr Thr Lys Lys 1460 - # 1465 - # 1470 - - Val Ser Arg Leu Glu Cys Arg Gly Gly Cys Al - #a Gly Gly Gln Cys Cys 1475 - # 1480 - # 1485 - - Gly Pro Leu Arg Ser Lys Arg Arg Lys Tyr Se - #r Phe Glu Cys Thr Asp 1490 - # 1495 - # 1500 - - Gly Ser Ser Phe Val Asp Glu Val Glu Lys Va - #l Val Lys Cys Gly Cys 1505 1510 - # 1515 - # 1520 - - Thr Arg Cys Val Ser 1525 - - - - <210> SEQ ID NO 3 <211> LENGTH: 105 <212> TYPE: PRT <213> ORGANISM: human - - <400> SEQUENCE: 3 - - Ser Pro Cys Thr Cys Ser Asn Asn Ile Val As - #p Cys Arg Gly Lys Gly 1 5 - # 10 - # 15 - - Leu Met Glu Ile Pro Ala Asn Leu Pro Glu Gl - #y Ile Val Glu Ile Arg 20 - # 25 - # 30 - - Leu Glu Gln Asn Ser Ile Lys Ala Ile Pro Al - #a Gly Ala Phe Thr Gln 35 - # 40 - # 45 - - Tyr Lys Lys Leu Lys Arg Ile Asp Ile Ser Ly - #s Asn Gln Ile Ser Asp 50 - # 55 - # 60 - - Ile Ala Pro Asp Ala Phe Gln Gly Leu Lys Se - #r Leu Thr Ser Leu Val 65 - # 70 - # 75 - # 80 - - Leu Tyr Gly Asn Lys Ile Thr Glu Ile Ala Ly - #s Gly Leu Phe Asp Gly 85 - # 90 - # 95 - - Leu Val Ser Leu Gln Leu Leu Leu Leu 100 - # 105 - - - - <210> SEQ ID NO 4 <211> LENGTH: 138 <212> TYPE: PRT <213> ORGANISM: human - - <400> SEQUENCE: 4 - - - - Glu Gly Ala Phe Asn Gly Ala Ala Ser Val Gl - #n Glu Leu MetLeu Thr 1 5 - # 10 - # 15 - - Gly Asn Gln Leu Glu Thr Val His Gly Arg Gl - #y Phe Arg Gly Gly Leu 20 - # 25 - # 30 - - Ser Gly Leu Lys Thr Leu Met Leu Arg Ser As - #n Leu Ile Gly Cys Val 35 - # 40 - # 45 - - Ser Asn Asp Thr Phe Ala Gly Leu Ser Ser Va - #l Arg Leu Leu Ser Leu 50 - # 55 - # 60 - - Tyr Asp Asn Arg Ile Thr Thr Ile Thr Pro Gl - #y Ala Phe Thr Thr Leu 65 - # 70 - # 75 - # 80 - - Val Ser Leu Ser Thr Ile Asn Leu Leu Ser As - #n Pro Phe Asn Cys Asn 85 - # 90 - # 95 - - Cys His Leu Gly Ala Gly Leu Gly Lys Trp Le - #u Arg Lys Arg Arg Ile 100 - # 105 - # 110 - - Val Ser Gly Asn Pro Arg Cys Gln Lys Pro Ph - #e Phe Leu Lys Glu Ile 115 - # 120 - # 125 - - Pro Ile Gln Gly Val Gly His Pro Gly Ile 130 - # 135 - - - - <210> SEQ ID NO 5 <211> LENGTH: 160 <212> TYPE: PRT <213> ORGANISM: human - - <400> SEQUENCE: 5 - - Trp Pro Arg Cys Glu Cys Met Pro Gly Tyr Al - #a Gly Asp Asn Cys Ser 1 5 - # 10 - # 15 - - Glu Asn Gln Asp Asp Cys Arg Asp His Arg Cy - #s Gln Asn Gly Ala Gln 20 - # 25 - # 30 - - Cys Met Asp Glu Val Asn Ser Tyr Ser Cys Le - #u Cys Ala Glu Gly Tyr 35 - # 40 - # 45 - - Ser Gly Gln Leu Cys Glu Ile Pro Pro His Le - #u Pro Ala Pro Lys Ser 50 - # 55 - # 60 - - Pro Cys Glu Gly Thr Glu Cys Gln Asn Gly Al - #a Asn Cys Val Asp Gln 65 - # 70 - # 75 - # 80 - - Gly Asn Arg Pro Val Cys Gln Cys Leu Pro Gl - #y Phe Gly Gly Pro Glu 85 - # 90 - # 95 - - Cys Glu Lys Leu Leu Ser Val Asn Phe Val As - #p Arg Asp Thr Tyr Leu 100 - # 105 - # 110 - - Gln Phe Thr Asp Leu Gln Asn Trp Xaa Arg Xa - #a Asn Ile Thr Leu Gln 115 - # 120 - # 125 - - Val Phe Thr Ala Glu Asp Asn Gly Ile Leu Le - #u Tyr Asn Gly Gly Asn 130 - # 135 - # 140 - - Asp His Ile Ala Val Xaa Leu Tyr Xaa Gly Hi - #s Val Arg Phe Ser Tyr 145 1 - #50 1 - #55 1 -#60 - - - - <210> SEQ ID NO 6 <211> LENGTH: 103 <212> TYPE: PRT <213> ORGANISM: human - - <400> SEQUENCE: 6 - - Gln Cys His Ile Ser Asp Gln Gly Glu Pro Ty - #r Cys Leu Cys GlnPro 1 5 - # 10 - # 15 - - Gly Phe Ser Gly Glu His Cys Gln Gln Glu As - #n Pro Cys Leu Gly Gln 20 - # 25 - # 30 - - Val Val Arg Glu Val Ile Arg Arg Gln Lys Gl - #y Tyr Ala Ser Cys Ala 35 - # 40 - # 45 - - Thr Ala Ser Lys Val Pro Ile Met Glu Cys Ar - #g Gly Gly Cys Gly Pro 50 - # 55 - # 60 - - Gln Cys Cys Gln Pro Thr Arg Ser Lys Arg Ar - #g Lys Tyr Val Phe Gln 65 - # 70 - # 75 - # 80 - - Cys Thr Asp Gly Ser Ser Phe Val Glu Glu Va - #l Glu Arg His Leu Glu 85 - # 90 - # 95 - - Cys Gly Cys Leu Ala Cys Ser 100 - - - - <210> SEQ ID NO 7 <211> LENGTH: 1480 <212> TYPE: PRT <213> ORGANISM: Drosophila melanogaster - - <400> SEQUENCE: 7 - - Met Ala Ala Pro Ser Arg Thr Thr Leu Met Pr - #o Pro Pro Phe Arg Leu 1 5 - # 10 - # 15 - - Gln Leu Arg Leu Leu Ile Leu Pro Ile Leu Le - #u Leu Leu Arg His Asp 20 - # 25 - # 30 - - Ala Val His Ala Glu Pro Tyr Ser Gly Gly Ph - #e Gly Ser Ser Ala Val 35 - # 40 - # 45 - - Ser Ser Gly Gly Leu Gly Ser Val Gly Ile Hi - #s Ile Pro Gly Gly Gly 50 - # 55 - # 60 - - Val Gly Val Ile Thr Glu Ala Arg Cys Pro Ar - #g Val Cys Ser Cys Thr 65 - # 70 - # 75 - # 80 - - Gly Leu Asn Val Asp Cys Ser His Arg Gly Le - #u Thr Ser Val Pro Arg 85 - # 90 - # 95 - - Lys Ile Ser Ala Asp Val Glu Arg Leu Glu Le - #u Gln Gly Asn Asn Leu 100 - # 105 - # 110 - - Thr Val Ile Tyr Glu Thr Asp Phe Gln Arg Le - #u Thr Lys Leu Arg Met 115 - # 120 - # 125 - - Leu Gln Leu Thr Asp Asn Gln Ile His Thr Il - #e Glu Arg Asn Ser Phe 130 - # 135 - # 140 - - Gln Asp Leu Val Ser Leu Glu Arg Leu Asp Il - #e Ser Asn Asn Val Ile 145 1 - #50 1 - #55 1 -#60 - - Thr Thr Val Gly Arg Arg Val Phe Lys Gly Al - #a Gln Ser Leu ArgSer 165 - # 170 - # 175 - - Leu Gln Leu Asp Asn Asn Gln Ile Thr Cys Le - #u Asp Glu His Ala Phe 180 - # 185 - # 190 - - Lys Gly Leu Val Glu Leu Glu Ile Leu Thr Le - #u Asn Asn Asn Asn Leu 195 - # 200 - # 205 - - Thr Ser Leu Pro His Asn Ile Phe Gly Gly Le - #u Gly Arg Leu Arg Ala 210 - # 215 - # 220 - - Leu Arg Leu Ser Asp Asn Pro Phe Ala Cys As - #p Cys His Leu Ser Trp 225 2 - #30 2 - #35 2 -#40 - - Leu Ser Arg Phe Leu Arg Ser Ala Thr Arg Le - #u Ala Pro Tyr ThrArg 245 - # 250 - # 255 - - Cys Gln Ser Pro Ser Gln Leu Lys Gly Gln As - #n Val Ala Asp Leu His 260 - # 265 - # 270 - - Asp Gln Glu Phe Lys Cys Ser Gly Leu Thr Gl - #u His Ala Pro Met Glu 275 - # 280 - # 285 - - Cys Gly Ala Glu Asn Ser Cys Pro His Pro Cy - #s Arg Cys Ala Asp Gly 290 - # 295 - # 300 - - Ile Val Asp Cys Arg Glu Lys Ser Leu Thr Se - #r Val Pro Val Thr Leu 305 3 - #10 3 - #15 3 -#20 - - Pro Asp Asp Thr Thr Asp Val Arg Leu Glu Gl - #n Asn Phe Ile ThrGlu 325 - # 330 - # 335 - - Leu Pro Pro Lys Ser Phe Ser Ser Phe Arg Ar - #g Leu Arg Arg Ile Asp 340 - # 345 - # 350 - - Leu Ser Asn Asn Asn Ile Ser Arg Ile Ala Hi - #s Asp Ala Leu Ser Gly 355 - # 360 - # 365 - - Leu Lys Gln Leu Thr Thr Leu Val Leu Tyr Gl - #y Asn Lys Ile Lys Asp 370 - # 375 - # 380 - - Leu Pro Ser Gly Val Phe Lys Gly Leu Gly Se - #r Leu Arg Leu Leu Leu 385 3 - #90 3 - #95 4 -#00 - - Leu Asn Ala Asn Glu Ile Ser Cys Ile Arg Ly - #s Asp Ala Phe ArgAsp 405 - # 410 - # 415 - - Leu His Ser Leu Ser Leu Leu Ser Leu Tyr As - #p Asn Asn Ile Gln Ser 420 - # 425 - # 430 - - Leu Ala Asn Gly Thr Phe Asp Ala Met Lys Se - #r Met Lys Thr Val His 435 - # 440 - # 445 - - Leu Ala Lys Asn Pro Phe Ile Cys Asp Cys As - #n Leu Arg Trp Leu Ala 450 - # 455 - # 460 - - Asp Tyr Leu His Lys Asn Pro Ile Glu Thr Se - #r Gly Ala Arg Cys Glu 465 4 - #70 4 - #75 4 -#80 - - Ser Pro Lys Arg Met His Arg Arg Arg Ile Gl - #u Ser Leu Arg GluGlu 485 - # 490 - # 495 - - Lys Phe Lys Cys Ser Trp Gly Glu Leu Arg Me - #t Lys Leu Ser Gly Glu 500 - # 505 - # 510 - - Cys Arg Met Asp Ser Asp Cys Pro Ala Met Cy - #s His Cys Glu Gly Thr 515 - # 520 - # 525 - - Thr Val Asp Cys Thr Gly Arg Arg Leu Lys Gl - #u Ile Pro Arg Asp Ile 530 - # 535 - # 540 - - Pro Leu His Thr Thr Glu Leu Leu Leu Asn As - #p Asn Glu Leu Gly Arg 545 5 - #50 5 - #55 5 -#60 - - Ile Ser Ser Asp Gly Leu Phe Gly Arg Leu Pr - #o His Leu Val LysLeu 565 - # 570 - # 575 - - Glu Leu Lys Arg Asn Gln Leu Thr Gly Ile Gl - #u Pro Asn Ala Phe Glu 580 - # 585 - # 590 - - Gly Ala Ser His Ile Gln Glu Leu Gln Leu Gl - #y Glu Asn Lys Ile Lys 595 - # 600 - # 605 - - Glu Ile Ser Asn Lys Met Phe Leu Gly Leu Hi - #s Gln Leu Lys Thr Leu 610 - # 615 - # 620 - - Asn Leu Tyr Asp Asn Gln Ile Ser Cys Val Me - #t Pro Gly Ser Phe Glu 625 6 - #30 6 - #35 6 -#40 - - His Leu Asn Ser Leu Thr Ser Leu Asn Leu Al - #a Ser Asn Pro PheAsn 645 - # 650 - # 655 - - Cys Asn Cys His Leu Ala Trp Phe Ala Glu Cy - #s Val Arg Lys Lys Ser 660 - # 665 - # 670 - - Leu Asn Gly Gly Ala Ala Arg Cys Gly Ala Pr - #o Ser Lys Val Arg Asp 675 - # 680 - # 685 - - Val Gln Ile Lys Asp Leu Pro His Ser Glu Ph - #e Lys Cys Ser Ser Glu 690 - # 695 - # 700 - - Asn Ser Glu Gly Cys Leu Gly Asp Gly Tyr Cy - #s Pro Pro Ser Cys Thr 705 7 - #10 7 - #15 7 -#20 - - Cys Thr Gly Thr Val Val Ala Cys Ser Arg As - #n Gln Leu Lys GluIle 725 - # 730 - # 735 - - Pro Arg Gly Ile Pro Ala Glu Thr Ser Glu Le - #u Tyr Leu Glu Ser Asn 740 - # 745 - # 750 - - Glu Ile Glu Gln Ile His Tyr Glu Arg Ile Ar - #g His Leu Arg Ser Leu 755 - # 760 - # 765 - - Thr Arg Leu Asp Leu Ser Asn Asn Gln Ile Th - #r Ile Leu Ser Asn Tyr 770 - # 775 - # 780 - - Thr Phe Ala Asn Leu Thr Lys Leu Ser Thr Le - #u Ile Ile Ser Tyr Asn 785 7 - #90 7 - #95 8 -#00 - - Lys Leu Gln Cys Leu Gln Arg His Ala Leu Se - #r Gly Leu Asn AsnLeu 805 - # 810 - # 815 - - Arg Val Val Ser Leu His Gly Asn Arg Ile Se - #r Met Leu Pro Glu Gly 820 - # 825 - # 830 - - Ser Phe Glu Asp Leu Lys Ser Leu Thr His Il - #e Ala Leu Gly Ser Asn 835 - # 840 - # 845 - - Pro Leu Tyr Cys Asp Cys Gly Leu Lys Trp Ph - #e Ser Asp Trp Ile Lys 850 - # 855 - # 860 - - Leu Asp Tyr Val Glu Pro Gly Ile Ala Arg Cy - #s Ala Glu Pro Glu Gln 865 8 - #70 8 - #75 8 -#80 - - Met Lys Asp Lys Leu Ile Leu Ser Thr Pro Se - #r Ser Ser Phe ValCys 885 - # 890 - # 895 - - Arg Gly Arg Val Arg Asn Asp Ile Leu Ala Ly - #s Cys Asn Ala Cys Phe 900 - # 905 - # 910 - - Glu Gln Pro Cys Gln Asn Gln Ala Gln Cys Va - #l Ala Leu Pro Gln Arg 915 - # 920 - # 925 - - Glu Tyr Gln Cys Leu Cys Gln Pro Gly Tyr Hi - #s Gly Lys His Cys Glu 930 - # 935 - # 940 - - Phe Met Ile Asp Ala Cys Tyr Gly Asn Pro Cy - #s Arg Asn Asn Ala Thr 945 9 - #50 9 - #55 9 -#60 - - Cys Thr Val Leu Glu Glu Gly Arg Phe Ser Cy - #s Gln Cys Ala ProGly 965 - # 970 - # 975 - - Tyr Thr Gly Ala Arg Cys Glu Thr Asn Ile As - #p Asp Cys Leu Gly Glu 980 - # 985 - # 990 - - Ile Lys Cys Gln Asn Asn Ala Thr Cys Ile As - #p Gly Val Glu Ser Tyr 995 - # 1000 - # 1005 - - Lys Cys Glu Cys Gln Pro Gly Phe Ser Gly Gl - #u Phe Cys Asp Thr Lys 1010 - # 1015 - # 1020 - - Ile Gln Phe Cys Ser Pro Glu Phe Asn Pro Cy - #s Ala Asn Gly Ala Lys 1025 1030 - # 1035 - # 1040 - - Cys Met Asp His Phe Thr His Tyr Ser Cys As - #p Cys Gln Ala Gly Phe 1045 - # 1050 - # 1055 - - His Gly Thr Asn Cys Thr Asp Asn Ile Asp As - #p Cys Gln Asn His Met 1060 - # 1065 - # 1070 - - Cys Gln Asn Gly Gly Thr Cys Val Asp Gly Il - #e Asn Asp Tyr Gln Cys 1075 - # 1080 - # 1085 - - Arg Cys Pro Asp Asp Tyr Thr Gly Lys Tyr Cy - #s Glu Gly His Asn Met 1090 - # 1095 - # 1100 - - Ile Ser Met Met Tyr Pro Gln Thr Ser Pro Cy - #s Gln Asn His Glu Cys 1105 1110 - # 1115 - # 1120 - - Lys His Gly Val Cys Phe Gln Pro Asn Ala Gl - #n Gly Ser Asp Tyr Leu 1125 - # 1130 - # 1135 - - Cys Arg Cys His Pro Gly Tyr Thr Gly Lys Tr - #p Cys Glu Tyr Leu Thr 1140 - # 1145 - # 1150 - - Ser Ile Ser Phe Val His Asn Asn Ser Phe Va - #l Glu Leu Glu Pro Leu 1155 - # 1160 - # 1165 - - Arg Thr Arg Pro Glu Ala Asn Val Thr Ile Va - #l Phe Ser Ser Ala Glu 1170 - # 1175 - # 1180 - - Gln Asn Gly Ile Leu Met Tyr Asp Gly Gln As - #p Ala His Leu Ala Val 1185 1190 - # 1195 - # 1200 - - Glu Leu Phe Asn Gly Arg Ile Arg Val Ser Ty - #r Asp Val Gly Asn His 1205 - # 1210 - # 1215 - - Pro Val Ser Thr Met Tyr Ser Phe Glu Met Va - #l Ala Asp Gly Lys Tyr 1220 - # 1225 - # 1230 - - His Ala Val Glu Leu Leu Ala Ile Lys Lys As - #n Phe Thr Leu Arg Val 1235 - # 1240 - # 1245 - - Asp Arg Gly Leu Ala Arg Ser Ile Ile Asn Gl - #u Gly Ser Asn Asp Tyr 1250 - # 1255 - # 1260 - - Leu Lys Leu Thr Thr Pro Met Phe Leu Gly Gl - #y Leu Pro Val Asp Pro 1265 1270 - # 1275 - # 1280 - - Ala Gln Gln Ala Tyr Lys Asn Trp Gln Ile Ar - #g Asn Leu Thr Ser Phe 1285 - # 1290 - # 1295 - - Lys Gly Cys Met Lys Glu Val Trp Ile Asn Hi - #s Lys Leu Val Asp Phe 1300 - # 1305 - # 1310 - - Gly Asn Ala Gln Arg Gln Gln Lys Ile Thr Pr - #o Gly Cys Ala Leu Leu 1315 - # 1320 - # 1325 - - Glu Gly Glu Gln Gln Glu Glu Glu Asp Asp Gl - #u Gln Asp Phe Met Asp 1330 - # 1335 - # 1340 - - Glu Thr Pro His Ile Lys Glu Glu Pro Val As - #p Pro Cys Leu Glu Asn 1345 1350 - # 1355 - # 1360 - - Lys Cys Arg Arg Gly Ser Arg Cys Val Pro As - #n Ser Asn Ala Arg Asp 1365 - # 1370 - # 1375 - - Gly Tyr Gln Cys Lys Cys Lys His Gly Gln Ar - #g Gly Arg Tyr Cys Asp 1380 - # 1385 - # 1390 - - Gln Gly Glu Gly Ser Thr Glu Pro Pro Thr Va - #l Thr Ala Ala Ser Thr 1395 - # 1400 - # 1405 - - Cys Arg Lys Glu Gln Val Arg Glu Tyr Tyr Th - #r Glu Asn Asp Cys Arg 1410 - # 1415 - # 1420 - - Ser Arg Gln Pro Leu Lys Tyr Ala Lys Cys Va - #l Gly Gly Cys Gly Asn 1425 1430 - # 1435 - # 1440 - - Gln Cys Cys Ala Ala Lys Ile Val Arg Arg Ar - #g Lys Val Arg Met Val 1445 - # 1450 - # 1455 - - Cys Ser Asn Asn Arg Lys Tyr Ile Lys Asn Le - #u Asp Ile Val Arg Lys 1460 - # 1465 - # 1470 - - Cys Gly Cys Thr Lys Lys Cys Tyr 1475 - # 1480 - - - - <210> SEQ ID NO 8 <211> LENGTH: 155 <212> TYPE: PRT <213> ORGANISM: Caenorhabditis elegans - - <400> SEQUENCE: 8 - - Arg Asn Pro Xaa Ile Cys Asp Cys Asn Leu Gl - #n Trp Leu Ala Gln Ile 1 5 - # 10 - # 15 - - Asn Leu Gln Lys Asn Ile Glu Thr Ser Gly Al - #a Arg Cys Glu Gln Pro 20 - # 25 - # 30 - - Lys Arg Leu Arg Lys Lys Lys Phe Ala Thr Le - #u Pro Pro Asn Lys Phe 35 - # 40 - # 45 - - Lys Cys Lys Gly Ser Glu Ser Phe Val Ser Me - #t Tyr Ala Asp Ser Cys 50 - # 55 - # 60 - - Phe Ile Asp Ser Ile Cys Pro Thr Gln Cys As - #p Cys Tyr Gly Thr Thr 65 - # 70 - # 75 - # 80 - - Val Asp Cys Asn Lys Arg Gly Leu Asn Thr Il - #e Pro Thr Ser Ile Pro 85 - # 90 - # 95 - - Arg Phe Ala Thr Gln Leu Leu Leu Ser Gly As - #n Asn Ile Ser Thr Val 100 - # 105 - # 110 - - Asp Leu Asn Ser Asn Ile His Val Leu Glu As - #n Leu Glu Xaa Leu Asp 115 - # 120 - # 125 - - Leu Ser Asn Asn His Ile Thr Phe Ile Asn As - #p Lys Ser Phe Glu Lys 130 - # 135 - # 140 - - Leu Ser Lys Leu Arg Glu Leu Xaa Leu Asn As - #p 145 1 - #50 1 - #55 - - - - <210> SEQ ID NO 9 <211> LENGTH: 735 <212> TYPE: PRT <213> ORGANISM: Caenorhabditis elegans - - <400> SEQUENCE: 9 - - Ser Asn Lys Asn Leu Thr Ser Phe Pro Ser Ar - #g Ile Pro Phe Asp Thr 1 5 - # 10 - # 15 - - Thr Glu Leu Tyr Leu Asp Ala Asn Tyr Ile As - #n Glu Ile Pro Ala His 20 - # 25 - # 30 - - Asp Leu Asn Arg Leu Tyr Ser Leu Thr Lys Le - #u Asp Leu Ser His Asn 35 - # 40 - # 45 - - Arg Leu Ile Ser Leu Glu Asn Asn Thr Phe Se - #r Asn Leu Thr Arg Leu 50 - # 55 - # 60 - - Ser Thr Leu Ile Ile Ser Tyr Asn Lys Leu Ar - #g Cys Leu Gln Pro Leu 65 - # 70 - # 75 - # 80 - - Ala Phe Asn Gly Leu Asn Ala Leu Arg Ile Le - #u Ser Leu His Gly Asn 85 - # 90 - # 95 - - Asp Ile Ser Phe Leu Pro Gln Ser Ala Phe Se - #r Asn Leu Thr Ser Ile 100 - # 105 - # 110 - - Thr His Ile Ala Val Gly Ser Asn Ser Leu Ty - #r Cys Asp Cys Asn Met 115 - # 120 - # 125 - - Ala Trp Phe Ser Lys Trp Ile Lys Ser Lys Ph - #e Ile Glu Ala Gly Ile 130 - # 135 - # 140 - - Ala Arg Cys Glu Tyr Pro Asn Thr Val Ser As - #n Gln Leu Leu Leu Thr 145 1 - #50 1 - #55 1 -#60 - - Ala Gln Pro Tyr Gln Phe Thr Cys Asp Ser Ly - #s Val Pro Thr LysLeu 165 - # 170 - # 175 - - Ala Thr Lys Cys Asp Leu Cys Leu Asn Ser Pr - #o Cys Lys Asn Asn Ala 180 - # 185 - # 190 - - Ile Cys Glu Thr Thr Ser Ser Arg Lys Tyr Th - #r Cys Asn Cys Thr Pro 195 - # 200 - # 205 - - Gly Phe Tyr Gly Val His Cys Glu Asn Gln Il - #e Asp Ala Cys Tyr Gly 210 - # 215 - # 220 - - Ser Pro Cys Leu Asn Asn Ala Thr Cys Lys Va - #l Ala Gln Ala Gly Arg 225 2 - #30 2 - #35 2 -#40 - - Phe Asn Cys Tyr Cys Asn Lys Gly Phe Glu Gl - #y Asp Tyr Cys GluLys 245 - # 250 - # 255 - - Asn Ile Asp Asp Cys Val Asn Ser Lys Cys Gl - #u Asn Gly Gly Lys Cys 260 - # 265 - # 270 - - Val Asp Leu Val Arg Phe Cys Ser Glu Glu Le - #u Lys Asn Phe Gln Ser 275 - # 280 - # 285 - - Phe Gln Ile Asn Ser Tyr Arg Cys Asp Cys Pr - #o Met Glu Tyr Glu Gly 290 - # 295 - # 300 - - Lys His Cys Glu Asp Lys Leu Glu Tyr Cys Th - #r Lys Lys Leu Asn Pro 305 3 - #10 3 - #15 3 -#20 - - Cys Glu Asn Asn Gly Lys Cys Ile Pro Ile As - #n Gly Ser Tyr SerCys 325 - # 330 - # 335 - - Met Cys Ser Pro Gly Phe Thr Gly Asn Asn Cy - #s Glu Thr Asn Ile Asp 340 - # 345 - # 350 - - Asp Cys Lys Asn Val Glu Cys Gln Asn Gly Gl - #y Ser Cys Val Asp Gly 355 - # 360 - # 365 - - Ile Leu Ser Tyr Asp Cys Leu Cys Arg Pro Gl - #y Tyr Ala Gly Gln Tyr 370 - # 375 - # 380 - - Cys Glu Ile Pro Pro Met Met Asp Met Glu Ty - #r Gln Lys Thr Asp Ala 385 3 - #90 3 - #95 4 -#00 - - Cys Gln Gln Ser Ala Cys Gly Gln Gly Glu Cy - #s Val Ala Ser GlnAsn 405 - # 410 - # 415 - - Ser Ser Asp Phe Thr Cys Lys Cys His Glu Gl - #y Phe Ser Gly Pro Ser 420 - # 425 - # 430 - - Cys Asp Arg Gln Met Ser Val Gly Phe Lys As - #n Pro Gly Ala Tyr Leu 435 - # 440 - # 445 - - Ala Leu Asp Pro Leu Ala Ser Asp Gly Thr Il - #e Thr Met Thr Leu Arg 450 - # 455 - # 460 - - Thr Thr Ser Lys Ile Gly Ile Leu Leu Tyr Ty - #r Gly Asp Asp His Phe 465 4 - #70 4 - #75 4 -#80 - - Val Ser Ala Glu Leu Tyr Asp Gly Arg Val Ly - #s Leu Val Tyr TyrIle 485 - # 490 - # 495 - - Gly Asn Phe Pro Ala Ser His Met Tyr Ser Se - #r Val Lys Val Asn Asp 500 - # 505 - # 510 - - Gly Leu Pro His Arg Ile Ser Ile Arg Thr Se - #r Glu Arg Lys Cys Phe 515 - # 520 - # 525 - - Leu Gln Ile Asp Lys Asn Pro Val Gln Ile Va - #l Glu Asn Ser Gly Lys 530 - # 535 - # 540 - - Ser Asp Gln Leu Ile Thr Lys Gly Lys Glu Me - #t Leu Tyr Ile Gly Gly 545 5 - #50 5 - #55 5 -#60 - - Leu Pro Ile Glu Lys Ser Gln Asp Ala Lys Ar - #g Arg Phe His ValLys 565 - # 570 - # 575 - - Asn Ser Glu Ser Leu Lys Gly Cys Ile Ser Se - #r Ile Thr Ile Asn Glu 580 - # 585 - # 590 - - Val Pro Ile Asn Leu Gln Gln Ala Leu Glu As - #n Val Asn Thr Glu Gln 595 - # 600 - # 605 - - Ser Cys Ser Ala Thr Val Asn Phe Cys Ala Gl - #y Ile Asp Cys Gly Asn 610 - # 615 - # 620 - - Gly Lys Cys Thr Asn Asn Ala Leu Ser Pro Ly - #s Gly Tyr Met Cys Gln 625 6 - #30 6 - #35 6 -#40 - - Cys Asp Ser His Phe Ser Gly Glu His Cys As - #p Glu Lys Arg IleLys 645 - # 650 - # 655 - - Cys Asp Lys Gln Lys Phe Arg Arg His His Il - #e Glu Asn Glu Cys Arg 660 - # 665 - # 670 - - Ser Val Asp Arg Ile Lys Ile Ala Glu Cys As - #n Gly Tyr Cys Gly Gly 675 - # 680 - # 685 - - Glu Gln Asn Cys Cys Thr Ala Val Lys Lys Ly - #s Gln Arg Lys Val Lys 690 - # 695 - # 700 - - Met Ile Cys Lys Asn Gly Thr Thr Lys Ile Se - #r Thr Val His Ile Ile 705 7 - #10 7 - #15 7 -#20 - - Arg Gln Cys Gln Cys Glu Pro Thr Lys Ser Va - #l Leu Ser Glu Lys 725 - # 730 - # 735 - - - - <210> SEQ ID NO 10 <211> LENGTH: 154 <212> TYPE: PRT <213> ORGANISM: mouse - - <400> SEQUENCE: 10 - - Asp Pro Leu Pro Val His His Arg Cys Glu Cy - #s Met Leu Gly Tyr Thr 1 5 - # 10 - # 15 - - Gly Asp Asn Cys Ser Glu Asn Gln Asp Asp Cy - #s Lys Asp His Lys Cys 20 - # 25 - # 30 - - Gln Asn Gly Ala Gln Cys Val Asp Glu Val As - #n Ser Tyr Ala Cys Leu 35 - # 40 - # 45 - - Cys Val Glu Gly Tyr Ser Gly Gln Leu Cys Gl - #u Ile Pro Pro Ala Pro 50 - # 55 - # 60 - - Arg Ser Ser Cys Glu Gly Thr Glu Cys Gln As - #n Gly Ala Asn Cys Val 65 - # 70 - # 75 - # 80 - - Asp Gln Gly Ser Arg Pro Val Cys Gln Cys Le - #u Pro Gly Phe Gly Gly 85 - # 90 - # 95 - - Pro Glu Cys Glu Lys Leu Leu Ser Val Asn Ph - #e Val Asp Arg Asp Thr 100 - # 105 - # 110 - - Tyr Leu Gln Phe Thr Asp Leu Gln Asn Trp Pr - #o Arg Ala Asn Ile Thr 115 - # 120 - # 125 - - Leu Gln Val Ser Thr Ala Glu Asp Asn Gly Il - #e Leu Leu Tyr Asn Gly 130 - # 135 - # 140 - - Asp Asn Asp His Ile Ala Val Glu Leu Tyr 145 1 - #50 - - - - <210> SEQ ID NO 11 <211> LENGTH: 110 <212> TYPE: PRT <213> ORGANISM: mouse - - <400> SEQUENCE: 11 - - Ala Phe Lys Cys His His Gly Gln Cys His Il - #e Ser Asp Arg Gly Glu 1 5 - # 10 - # 15 - - Pro Tyr Cys Leu Cys Gln Pro Gly Phe Ser Gl - #y His His Cys Glu Gln 20 - # 25 - # 30 - - Glu Asn Pro Cys Met Gly Glu Ile Val Arg Gl - #u Ala Ile Arg Arg Gln 35 - # 40 - # 45 - - Lys Asp Tyr Ala Ser Cys Ala Thr Ala Ser Ly - #s Val Pro Ile Met Glu 50 - # 55 - # 60 - - Cys Arg Gly Gly Cys Gly Thr Thr Cys Cys Gl - #n Pro Ile Arg Ser Lys 65 - # 70 - # 75 - # 80 - - Arg Arg Lys Tyr Val Phe Gln Cys Thr Asp Gl - #y Ser Ser Phe Val Glu 85 - # 90 - # 95 - - Glu Val Glu Arg His Leu Glu Cys Gly Cys Ar - #g Ala Cys Ser 100 - # 105 - # 110 - - - - <210> SEQ ID NO 12 <211> LENGTH: 134 <212> TYPE: PRT <213> ORGANISM: mouse - - <400> SEQUENCE: 12 - - His Leu Arg Val Leu Gln Leu Met Glu Asn Ar - #g Ile Ser Thr Ile Glu 1 5 - # 10 - # 15 - - Arg Gly Ala Phe Gln Asp Leu Lys Glu Leu Gl - #u Arg Leu Arg Leu Asn 20 - # 25 - # 30 - - Arg Asn Asn Leu Gln Leu Phe Pro Glu Leu Le - #u Phe Leu Gly Thr Ala 35 - # 40 - # 45 - - Arg Leu Tyr Arg Leu Asp Leu Ser Glu Asn Gl - #n Ile Gln Ala Ile Pro 50 - # 55 - # 60 - - Arg Lys Ala Phe Arg Gly Ala Val Asp Ile Ly - #s Asn Leu Gln Leu Asp 65 - # 70 - # 75 - # 80 - - Tyr Asn Gln Ile Ser Cys Ile Glu Asp Gly Al - #a Phe Arg Ala Leu Arg 85 - # 90 - # 95 - - Asp Leu Glu Val Leu Thr Leu Asn Asn Asn As - #n Ile Thr Arg Leu Ser 100 - # 105 - # 110 - - Val Ala Ser Phe Asn His Met Pro Lys Leu Ar - #g Thr Phe Arg Leu His 115 - # 120 - # 125 - - Ser Asn Asn Leu Tyr Cys 130 - - - - <210> SEQ ID NO 13 <211> LENGTH: 104 <212> TYPE: PRT <213> ORGANISM: mouse - - <400> SEQUENCE: 13 - - Asn Asn Asp Asp Cys Val Gly His Lys Cys Ar - #g His Gly Ala Gln Cys 1 5 - # 10 - # 15 Val Asp Glu Val Asn Gly Tyr Thr Cys Ile Cy - #s Pro Gln Gly Phe Ser 20 - # 25 - # 30 Gly Leu Phe Cys Glu His Pro Pro Pro Met Va - #l Leu Leu Gln Thr Ser 35 - # 40 - # 45 Pro Cys Asp Gln Tyr Glu Cys Gln Asn Gly Al - #a Gln Cys Ile Val Val 50 - # 55 - # 60 Gln Gln Glu Pro Thr Cys Arg Cys Pro Pro Gl - #y Phe Ala Gly Pro Arg 65 - # 70 - # 75 - # 80 Cys Glu Lys Leu Ile Thr Val Asn Phe Val Gl - #y Lys Asp Ser Tyr Val 85 - # 90 - # 95 Glu Leu Ala Ser Ala Lys Val Arg 100 - - - - <210> SEQ ID NO 14 <211> LENGTH: 243 <212> TYPE: PRT <213> ORGANISM: mouse - - <400> SEQUENCE: 14 - - Ile Leu Asp Val Ala Ser Leu Arg Gln Ala Pr - #o Gly Glu Asn Gly Thr 1 5 - # 10 - # 15 - - Ser Phe His Gly Cys Ile Arg Asn Leu Tyr Il - #e Asn Ser Glu Leu Gln 20 - # 25 - # 30 - - Asp Phe Arg Lys Met Pro Met Gln Thr Gly Il - #e Leu Pro Gly Cys Glu 35 - # 40 - # 45 - - Pro Cys His Lys Lys Val Cys Ala His Gly Cy - #s Cys Gln Pro Ser Ser 50 - # 55 - # 60 - - Gln Ser Gly Phe Thr Cys Glu Cys Glu Glu Gl - #y Trp Met Gly Pro Leu 65 - # 70 - # 75 - # 80 - - Cys Asp Gln Arg Thr Asn Asp Pro Cys Leu Gl - #y Asn Lys Cys Val His 85 - # 90 - # 95 - - Gly Thr Cys Leu Pro Ile Asn Ala Phe Ser Ty - #r Ser Cys Lys Cys Leu 100 - # 105 - # 110 - - Glu Gly His Gly Gly Val Leu Cys Asp Glu Gl - #u Glu Asp Leu Phe Asn 115 - # 120 - # 125 - - Pro Cys Gln Met Ile Lys Cys Lys His Gly Ly - #s Cys Arg Leu Ser Gly 130 - # 135 - # 140 - - Val Gly Gln Pro Tyr Cys Glu Cys Asn Ser Gl - #y Phe Thr Gly Asp Ser 145 1 - #50 1 - #55 1 -#60 - - Cys Asp Arg Glu Ile Ser Cys Arg Gly Glu Ar - #g Ile Arg Asp TyrTyr 165 - # 170 - # 175 - - Gln Lys Gln Gln Gly Tyr Ala Ala Cys Gln Th - #r Thr Lys Lys Val Ser 180 - # 185 - # 190 - - Arg Leu Glu Cys Arg Gly Gly Cys Ala Gly Gl - #y Gln Cys Cys Gly Pro 195 - # 200 - # 205 - - Leu Arg Ser Lys Arg Arg Lys Tyr Ser Phe Gl - #u Cys Thr Asp Gly Ser 210 - # 215 - # 220 - - Ser Phe Val Asp Glu Val Glu Lys Val Val Ly - #s Cys Gly Cys Ala Arg 225 2 - #30 2 - #35 2 -#40 - - Cys Ala Ser__________________________________________________________________________

Claims

1. An isolated polypeptide comprising at least one sequence selected from the group consisting of SEQ ID NOS:2-6, 8 and 10-14, or a subsequence thereof having at least 16 consecutive amino acids residues thereof and comprising one or more unboxed amino acid residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2.

2. An isolated polypeptide according to claim 1 comprising at least one sequence selected from the group consisting of SEQ ID NOS:2-6, 8 and 10-14, or a subsequence thereof having at least 64 consecutive amino acid residues thereof and comprising one or more unboxed amino acid residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2.

3. An isolated polypeptide comprising at least one sequence selected from the group consisting of SEQ ID NOS:2-6 and 8-14.

4. An isolated polypeptide according to claim 1 comprising at least one sequence selected from the group consisting of SEQ ID NOS:2-6, or a subsequence thereof having at least 16 consecutive amino acid residues thereof and comprising one or more unboxed amino acid residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2.

5. An isolated polypeptide according to claim 1 comprising SEQ ID NO:2, 3, 4, 5, or 6, or a subsequence thereof having at least 64 consecutive amino acid residues thereof and comprising one or more unboxed amino acid residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2.

6. An isolated polypeptide according to claim 1 comprising SEQ ID NO:2, or a subsequence thereof having at least 16 consecutive amino acid residues thereof and comprising one or more unboxed amino acid residues of the corresponding sequence in Table 2.

7. An isolated polypeptide according to claim 1 comprising SEQ ID NO:2, or a subsequence thereof having at least 64 consecutive amino acid residues thereof and comprising one or more unboxed amino acid residues of the corresponding sequence in Table 2.

8. An isolated polypeptide according to claim 1 comprising SEQ ID NO:2.

9. An isolated polypeptide according to claim 1, comprising at least one sequence selected from the group consisting of SEQ ID NO: 2, amino acid residues 1-10; SEQ ID NO: 2, amino acid residues 29-41; SEQ ID NO: 2, amino acid residues 75-87 SEQ ID NO: 2, amino acid residues 92-109; SEQ ID NO: 2, amino acid residues 132-141; SEQ ID NO: 2, amino acid residues 192-205; SEQ ID NO: 2, amino acid residues 228-269; SEQ ID NO: 2, amino acid residues 295-311; SEQ ID NO: 2, amino acid residues 316-330; SEQ ID NO: 2, amino acid residues 373-382; SEQ ID NO: 2, amino acid residues 403-422; SEQ ID NO: 2, amino acid residues 474-485 SEQ ID NO: 2, amino acid residues 561-576; SEQ ID NO: 2, amino acid residues 683-697; SEQ ID NO: 2, amino acid residues 768-777; SEQ ID NO: 2, amino acid residues 798-813; SEQ ID NO: 2, amino acid residues 882-894; SEQ ID NO: 2, amino acid residues 934-946; SEQ ID NO: 2, amino acid residues 1054-1067; SEQ ID NO: 2, amino acid residues 1181-1192; SEQ ID NO: 2, amino acid residues 1273-1299; SEQ ID NO: 2, amino acid residues 1384-1397; SEQ ID NO: 2, amino acid residues 1468-1477; SEQ ID NO: 2, amino acid residues 1508-1517.

10. An isolated polypeptide comprising at least one sequence selected from the group consisting of SEQ ID NOS:2-6 and 10-14, or a subsequence thereof having at least 16 consecutive amino acid residues thereof and comprising one or more unboxed amino acid residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2.

11. An isolated polypeptide according to claim 10 comprising at least one sequence selected from the group consisting of SEQ ID NOS:2-6 and 10-14, or a subsequence thereof having at least 64 consecutive amino acid residues thereof and comprising one or more unboxed amino acid residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2.

12. An isolated polypeptide according to claim 10 comprising at least one sequence selected from the group consisting of SEQ ID NOS:2-6 and 10-4.

13. A method of identifying agents which modulate the interaction of a Robo polypeptide and a Slit polypeptide which consists of the isolated polypeptide according to claim 1, said method comprising the steps of:

combining the Robo polypeptide, the Slit polypeptide, and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and

determining a second interaction of the Robo and Slit polypeptides in the presence of the agent,

wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides.

14. A method of identifying agents which modulate the interaction of a Robo polypeptide and a Slit polypeptide which consists of the isolated polypeptide according to claim 2, said method comprising the steps of:

combining the Robo polypeptide, the Slit polypeptide, and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and

determining a second interaction of the Robo and Slit polypeptides in the presence of the agent,

wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides.

15. A method of identifying agents which modulate the interaction of a Robo polypeptide and a Slit polypeptide which consists of the isolated polypeptide according to claim 5, said method comprising the steps of:

combining the Robo polypeptide, the Slit polypeptide, and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and

determining a second interaction of the Robo and Slit polypeptides in the presence of the agent,

wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides.

16. A method of identifying agents which modulate the interaction of a Robo polypeptide and a Slit polypeptide which consists of the isolated polypeptide according to claim 7, said method comprising the steps of:

combining the Robo polypeptide, the Slit polypeptide, and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and

determining a second interaction of the Robo and Slit polypeptides in the presence of the agent,

wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides.

17. A method of modulating the interaction of a Robo polypeptide and a Slit polypeptide which consists of the isolated polypeptide according to claim 1, said method comprising the steps of

combining the Robo polypeptide, the Slit polypeptide, and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, and whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction.

18. A method of modulating the interaction of a Robo polypeptide and a Slit polypeptide which consists of the isolated polypeptide according to claim 2, said method comprising the steps of

combining the Robo polypeptide, the Slit polypeptide, and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, and whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction.

19. A method of modulating the interaction of a Robo polypeptide and a Slit polypeptide which consists of the isolated polypeptide according to claim 5, said method comprising the steps of

combining the Robo polypeptide, the Slit polypeptide, and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, and whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction.

20. A method of modulating the interaction of a Robo polypeptide and a Slit polypeptide which consists of the isolated polypeptide according to claim 7, said method comprising the steps of

combining the Robo polypeptide, the Slit polypeptide, and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, and whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction.

21. A method according to claim 17, wherein the modulator is a fragment of the Robo or Slit polypeptide.